<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02974868</url>
  </required_header>
  <id_info>
    <org_study_id>B7931005</org_study_id>
    <secondary_id>2016-004048-13</secondary_id>
    <secondary_id>ALLEGRO</secondary_id>
    <nct_id>NCT02974868</nct_id>
  </id_info>
  <brief_title>Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata</brief_title>
  <official_title>A PHASE 2A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06651600 AND PF-06700841 IN SUBJECTS WITH MODERATE TO SEVERE ALOPECIA AREATA WITH A SINGLE-BLIND EXTENSION PERIOD AND A CROSS-OVER OPEN LABEL EXTENSION PERIOD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2a, randomized, double blind, parallel group, multicenter study with an&#xD;
      extension period. The study will have a maximum duration of approximately 113 weeks. This&#xD;
      includes an up to 5 weeks Screening Period, a 24 week Treatment Period, a 4 week Drug Holiday&#xD;
      (#1), an up to 12 month Single Blind (investigator open, sponsor open and subject blind)&#xD;
      Extension Period, a 4 week drug holiday (#2), a 6 month Cross Over Open Label Extension&#xD;
      Period and a 4 week Follow up Period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 15, 2016</start_date>
  <completion_date type="Actual">May 15, 2019</completion_date>
  <primary_completion_date type="Actual">May 15, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model_description>The first 24 weeks are parallel. The single-blind extension period will have a segment for non-responder and a withdrawal/retreatment segment for responder. The cross-over extension period is parallel for non-responders.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24</measure>
    <time_frame>Baseline, Week24</time_frame>
    <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. Score range: 0-100%. Higher score indicates more severe disease. Change from baseline is defined as the baseline value minus the value at a specific visit. Positive change from baseline signifies an improvement. Baseline is defined as the last measurement prior to first dosing (Day 1).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events (All-causality and Treatment-related) - Single-Blind Extension (SBE) Period</measure>
    <time_frame>Week 28 up to Week 52</time_frame>
    <description>An AE (non-serious and serious) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent Adverse Event (TEAE). Treatment-related TEAE were determined by investigators. Arms end with &quot;withdrawal Segment&quot; and &quot;retreatment segment&quot; described the same population while in different treatment segment .The reason why count on PF-06700841 differ by 1 participant is that 1 responder directly entered the retreatment segment and skipped the withdrawal segment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events (All-causality and Treatment-related) - Cross-Over Extension (COE) Period</measure>
    <time_frame>COE day 1 up to end of study</time_frame>
    <description>An AE (non-serious and serious) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent Adverse Event (TEAE). Treatment-related TEAE were determined by investigators.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Laboratory Abnormalities During SBE Period</measure>
    <time_frame>Week 28 up to Week 52 for non-responders and responders in the withdrawal segment, AT day 1 up to AT Week 24 for retreatment segment (AT=active treatment)</time_frame>
    <description>Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology(Hemoglobin, Hematocrit, RBC count, Reticulocyte count, Platelet count, WBC count with differential, Total neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes); serum chemistry (BUN and Creatinine, Cystatin C, Creatine Phosphokinase, Glucose , Na+, K+, Cl ,Ca++, Total CO2, AST, ALT, Total Indirect &amp; Direct Bilirubin, Alkaline phosphatase, Uric acid, Albumin,Total protein, Fasting lipid Profile Panel; urinalysis(pH, Glucose, Protein, Nitrites, Leukocyte esterase, Microscopy culture);Other(HIV, HBsAg, HBcAb, HepB reflex (HbsAB), if applicable, HCVAb, Serum pregnancy test, Urine pregnancy test, FSH, QFT G or other IGRA, or PPD, EBV, CMV, HSV1, HSV2, VZV, Skin swab for herpetiform rash, Skin swab for potential drug related rash).Retest/discontinuation criteria are defined in Protocol Appendix 6.1 and 6.2 respectively.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Numbers of Participants With Specific Clinical Laboratory Abnormalities During COE Period</measure>
    <time_frame>COE day 1 up to end of study</time_frame>
    <description>Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology(Hemoglobin, Hematocrit, RBC count, Reticulocyte count, Platelet count, WBC count with differential, Total neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes); serum chemistry (BUN and Creatinine, Cystatin C, Creatine Phosphokinase, Glucose , Na+, K+, Cl ,Ca++, Total CO2, AST, ALT, Total Indirect &amp; Direct Bilirubin, Alkaline phosphatase, Uric acid, Albumin,Total protein, Fasting lipid Profile Panel; urinalysis(pH, Glucose, Protein, Nitrites, Leukocyte esterase, Microscopy culture);Other(HIV, HBsAg, HBcAb, HepB reflex (HbsAB), if applicable, HCVAb, Serum pregnancy test, Urine pregnancy test, FSH, QFT G or other IGRA, or PPD, EBV, CMV, HSV1, HSV2, VZV, Skin swab for herpetiform rash, Skin swab for potential drug related rash).Retest/discontinuation criteria are defined in Protocol Appendix 6.1 and 6.2 respectively.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24 -AT/AU Participants</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. Change from baseline is defined as the baseline value minus the value at a specific visit. Positive change from baseline implies an improvement. Alopecia totalis (AT): derived as SALT score = 100% at baseline only. Alopecia universalis (AU): derived as SALT score = 100% and both eyelash and eyebrow assessments were &quot;none&quot; at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving SALT 30 at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 30 response is a 30% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The 90% CI was calculated using Chan and Zhang method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Severity of Alopecia Tool (SALT) Across Time (Treatment Period)</measure>
    <time_frame>Baseline, Weeks 2,4,6,8,12,16,20,24</time_frame>
    <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. The SALT score can vary from 0 to 100% with higher score indicates more severe disease. Baseline is defined as the last measurement prior to first dosing (Day 1). Change from baseline is defined as the baseline value minus the value at a specific visit. Positive change from baseline implies an improvement. Least Square Mean and 90% Confidence Interval of Arms (PF-06651600 and PF-06700841) are the Least Square Mean and 90% Confidence Interval for difference from placebo respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Severity of Alopecia Tool (SALT) Across Time (Treatment Period)</measure>
    <time_frame>Baseline, Weeks 2,4,6,8,12,16,20,24</time_frame>
    <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. The SALT score can vary from 0 to 100% with higher score indicates more severe disease. Baseline is defined as the last measurement prior to first dosing (Day 1). Percent change from baseline is defined as SALT baseline value minus SALT value at a specific visit divided by baseline and multiplying by 100. Positive change from baseline implies an improvement. Least Square Mean and 90% Confidence Interval of Arms (PF-06651600 and PF-06700841) are the Least Square Mean and 90% Confidence Interval for difference from placebo respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving SALT 30 Across Time (Treatment Period)</measure>
    <time_frame>Baseline, Weeks 2,4,6,8,12,16,20,24</time_frame>
    <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 30 response is a 30% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving SALT 50 Across Time (Treatment Period)</measure>
    <time_frame>Baseline, Weeks 2,4,6,8,12,16,20,24</time_frame>
    <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 50 response is a 50% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving SALT 75 Across Time (Treatment Period)</measure>
    <time_frame>Baseline, Weeks 2,4,6,8,12,16,20,24</time_frame>
    <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 75 response is a 75% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving SALT 90 Across Time (Treatment Period)</measure>
    <time_frame>Baseline, Weeks 2,4,6,8,12,16,20,24</time_frame>
    <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 90 response is a 90% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving SALT 100 Across Time (Treatment Period)</measure>
    <time_frame>Baseline, Weeks 2,4,6,8,12,16,20,24</time_frame>
    <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 100 response is a 100% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With the IGA Score Change (Treatment Period)</measure>
    <time_frame>baseline, Week 2,4,6,8,12,16,20,24</time_frame>
    <description>The clinical evaluator of alopecia areata (AA) will perform an assessment of the overall improvement of AA and assign an Investigator Global Assessment (IGA) score(ranging from 0 to 5) with higher score representing higher regrowth rate. Baseline is defined as the last measurement prior to first dosing (Day 1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events (All-causality and Treatment-related) - Treatment Period</measure>
    <time_frame>baseline up to Week 24</time_frame>
    <description>An AE (non-serious and serious) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent Adverse Event (TEAE). Treatment-related TEAE were determined by investigators.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Laboratory Abnormalities During Treatment Period</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology(Hemoglobin, Hematocrit, RBC count, Reticulocyte count, Platelet count, WBC count with differential, Total neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes); serum chemistry (BUN and Creatinine, Cystatin C, Creatine Phosphokinase, Glucose , Na+, K+, Cl ,Ca++, Total CO2, AST, ALT, Total Indirect &amp; Direct Bilirubin, Alkaline phosphatase, Uric acid, Albumin,Total protein, Fasting lipid Profile Panel; urinalysis(pH, Glucose, Protein, Nitrites, Leukocyte esterase, Microscopy culture);Other(HIV, HBsAg, HBcAb, HepB reflex (HbsAB), if applicable, HCVAb, Serum pregnancy test, Urine pregnancy test, FSH, QFT G or other IGRA, or PPD, EBV, CMV, HSV1, HSV2, VZV, Skin swab for herpetiform rash, Skin swab for potential drug related rash).Retest/discontinuation criteria are defined in Protocol Appendix 6.1 and 6.2 respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Achieve the Retreatment Criteria During the Withdrawal/Retreatment Part of the Extension Period Among Subjects Who Achieved Primary Endpoint at Week 24 (SBE Period)</measure>
    <time_frame>Week 24 up to Week 52</time_frame>
    <description>Time to re-treatment (weeks) = (date of re-treatment criteria met - date at Week 24 +1)/7. The calendar time to retreatment was calculated. Baseline is defined as Week 24 measurement. The duration in Drug Holiday #1 (ranging from 2-6 weeks) is counted in the Kaplan-Meier analysis. One subject directly entered the re-treatment period and hence is censored at baseline in the Kaplan-Meier analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SALT Across Time (SBE Period)</measure>
    <time_frame>Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)</time_frame>
    <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. The SALT score can vary from 0 to 100% with higher score indicates more severe disease. Baseline is defined as the last measurement prior to first dosing (Day 1). Change from baseline is defined as the baseline value minus the value at a specific visit. Positive change from baseline implies an improvement. Least Square Mean and 90% confidence interval in this outcome measurement is the LSM and 90%CI for difference from initial 24-week treatment period placebo respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving SALT 30 Across Time (SBE Period)</measure>
    <time_frame>Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)</time_frame>
    <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 30 response is a 30% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving SALT 50 Across Time (SBE Period)</measure>
    <time_frame>Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)</time_frame>
    <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 50 response is a 50% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving SALT 75 Across Time (SBE Period)</measure>
    <time_frame>Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)</time_frame>
    <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 75 response is a 75% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving SALT 90 Across Time (SBE Period)</measure>
    <time_frame>Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)</time_frame>
    <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 90 response is a 90% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving SALT 100 Across Time (SBE Period)</measure>
    <time_frame>Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)</time_frame>
    <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 100 response is a 100% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">142</enrollment>
  <condition>Alopecia Areata</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-06651600</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-06700841</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06651600</intervention_name>
    <description>200 mg QD during induction and 50 mg QD during Maintenance</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06700841</intervention_name>
    <description>60 mg QD during induction and 30 mg QD during maintenance</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Cohort placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects between 18 75 years of age, inclusive, at time of informed&#xD;
             consent.&#xD;
&#xD;
          -  Must have moderate to severe alopecia areata:&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of human immunodeficiency virus (HIV) or positive HIV serology at screening,&#xD;
&#xD;
          -  Infected with hepatitis B or hepatitis C viruses.&#xD;
&#xD;
          -  Have evidence of active or latent or inadequately treated infection with Mycobacterium&#xD;
             tuberculosis (TB)&#xD;
&#xD;
          -  Have received any of the following treatment regiments specified in the timeframes&#xD;
             outlined below:&#xD;
&#xD;
        Within 6 months of first dose of study drug: Any cell depleting agents Within 12 weeks of&#xD;
        first dose of study drug: Any studies with JAK inhibitors; Other biologics Within 8 weeks&#xD;
        of first dose of study drug: Participation in other studies involving investigational&#xD;
        drug(s) Within 6 weeks of first dose of study drug: Have been vaccinated with live or&#xD;
        attenuated live vaccine.&#xD;
&#xD;
        Within 4 weeks of first dose of study drug: Use of oral immune suppressants; Phototherapy&#xD;
        (NB UVB) or broad band phototherapy; Regular use (more than 2 visits per week) of a tanning&#xD;
        booth/parlor.&#xD;
&#xD;
        Within 2 week of first dose of study drug: Topical treatments that could affect AA; Herbal&#xD;
        medications with unknown properties or known beneficial effects for AA.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham, Dermatology at the Whitaker Clinic</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alabama at Birmingham, The Kirklin Clinic</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern California Dermatology, Inc.</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Science Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of F. Monte Purcelli</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tower Saint John's Imaging</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital Clinical and Translational Research Center, Inpatient Unit</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital Clinical and Translational Research Center, Outpatient Clinic</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital, Anschutz Cancer Pavilion</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Drug Services</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Church Street Research Unit</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale Hearing and Balance Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Park Avenue Dermatology Administrative Annex</name>
      <address>
        <city>Orange Park</city>
        <state>Florida</state>
        <zip>32073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Park Avenue Dermatology</name>
      <address>
        <city>Orange Park</city>
        <state>Florida</state>
        <zip>32073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edward B. Kampsen, MD</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Olympian Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rose Radiology</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forward Clinical Trials, Inc</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33624</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedaPhase Inc.</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <zip>30263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NorthShore University HealthSystem Dermatology Clinical Trials Unit</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60077</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dawes Fretzin Clinical Research Group, LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dawes Fretzin Dermatology Group, LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Clinical Unit for Research Trials in Skin (CURTIS)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Department of Otolaryngology</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rockefeller University Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Drug Service</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Audiology</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Radiology</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vital Prospects Clinical Research Institute, P.C.</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Concepts</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah MidValley Dermatology</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Clinical Research, Inc.</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hearing Life</name>
      <address>
        <city>Hurstville</city>
        <state>New South Wales</state>
        <zip>2220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Glen and Partners Medical Imaging</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St George Dermatology and Skin Cancer Centre</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. George Hearing and Balance Clinic</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Skin Centre</name>
      <address>
        <city>Benowa</city>
        <state>Queensland</state>
        <zip>4217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veracity Clinical Research</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin &amp; Cancer Foundation Inc.</name>
      <address>
        <city>Carlton</city>
        <state>Victoria</state>
        <zip>3053</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sinclair Dermatology</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bridge Road Imag ing</name>
      <address>
        <city>Richmond</city>
        <state>Victoria</state>
        <zip>3121</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Richmond Audiology</name>
      <address>
        <city>Richmond</city>
        <state>Victoria</state>
        <zip>3121</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wiseman Dermatology Research Inc.</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3M 3Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynderm Research Inc.</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research by ICLS</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6J 7W5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SKiN Centre for Dermatology</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9J 5K2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Centre for Dermatology</name>
      <address>
        <city>Richmond Hill</city>
        <state>Ontario</state>
        <zip>L4B 1A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>York Dermatology Center</name>
      <address>
        <city>Richmond Hill</city>
        <state>Ontario</state>
        <zip>L4C 9M7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=B7931005</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>November 23, 2016</study_first_submitted>
  <study_first_submitted_qc>November 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2016</study_first_posted>
  <results_first_submitted>May 6, 2020</results_first_submitted>
  <results_first_submitted_qc>May 6, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 26, 2020</results_first_posted>
  <last_update_submitted>May 6, 2020</last_update_submitted>
  <last_update_submitted_qc>May 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 2</keyword>
  <keyword>randomized</keyword>
  <keyword>double-blind</keyword>
  <keyword>placebo</keyword>
  <keyword>alopecia areata</keyword>
  <keyword>safety</keyword>
  <keyword>efficacy</keyword>
  <keyword>JAK</keyword>
  <keyword>janus kinase</keyword>
  <keyword>moderate</keyword>
  <keyword>severe</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>PF-06700841</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT02974868/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 12, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT02974868/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study had a 24 week Treatment Period, a 4 week Drug Holiday, an up to 48 weeks(24 weeks + additional 24 Weeks for those received active retreatment) Single Blind Extension Period, a 4 week Drug Holiday, a 24 weeks Cross Over Open Label Extension Period.</recruitment_details>
      <pre_assignment_details>Criteria for entering SBE: complete the former period without showing Key Exclusion defined in CSR Section 9.3.2.&#xD;
Criteria for entering COE: non-responders (SALT change from baseline &lt;30%) at Week 24 and continued to be non-responders at Week 52 in SBE period without showing Key Exclusion defined in CSR Section 9.3.2.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo for PF-06651600</title>
          <description>Participants received placebo tablets QD matching for PF-06651600.</description>
        </group>
        <group group_id="P2">
          <title>Placebo for PF-06700841</title>
          <description>Participants received placebo tablets QD matching for PF-06700841.</description>
        </group>
        <group group_id="P3">
          <title>PF-06651600</title>
          <description>Participants received PF-06651600 200 mg QD for 4 weeks induction period followed by PF-06651600 50 mg QD for a 20 weeks maintenance period.</description>
        </group>
        <group group_id="P4">
          <title>PF-06700841</title>
          <description>Participants received PF-06700841 60 mg tablets QD for a 4-week induction period followed by PF-06700841 30 mg tablets QD for a 20-week maintenance period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Initial 24-Week Treatment Period (TP)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="48"/>
                <participants group_id="P4" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="45"/>
                <participants group_id="P4" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>others</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Single-Blind Extension (SBE) Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="38"/>
                <participants group_id="P4" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="27"/>
                <participants group_id="P4" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>AE &amp; Withdraw by participants</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Cross-Over Extension (COE) Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants received at least 1 dose of PF-06651600,PF-06700841 or matching placebo.</population>
      <group_list>
        <group group_id="B1">
          <title>TP:Placebo</title>
          <description>Participants received placebo tablets QD both matching for PF-06651600 and PF-06700841.</description>
        </group>
        <group group_id="B2">
          <title>TP:PF-06651600</title>
          <description>Participants received PF-06651600 200 mg tablets QD for a 4-week induction period followed by PF-06651600 50 mg tablets QD for a 20-week maintenance period.</description>
        </group>
        <group group_id="B3">
          <title>TP:PF-06700841</title>
          <description>Participants received PF-06700841 60 mg tablets QD for a 4-week induction period followed by PF-06700841 30 mg tablets QD for a 20-week maintenance period.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="47"/>
            <count group_id="B2" value="48"/>
            <count group_id="B3" value="47"/>
            <count group_id="B4" value="142"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.17" spread="14.22"/>
                    <measurement group_id="B2" value="36.88" spread="12.62"/>
                    <measurement group_id="B3" value="33.94" spread="11.43"/>
                    <measurement group_id="B4" value="36.33" spread="12.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>18-44 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45-64 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="98"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="132"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24</title>
        <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. Score range: 0-100%. Higher score indicates more severe disease. Change from baseline is defined as the baseline value minus the value at a specific visit. Positive change from baseline signifies an improvement. Baseline is defined as the last measurement prior to first dosing (Day 1).</description>
        <time_frame>Baseline, Week24</time_frame>
        <population>Number of Participants Analyzed: All randomized participants assigned to the study treatment. Number Analyzed: Number of Participants with observed data at Week 24</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06651600</title>
            <description>Participants received PF-06651600 200 mg QD for 4 weeks induction period followed by PF-06651600 50 mg QD for a 20 weeks maintenance period.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841</title>
            <description>Participants received PF-06700841 60 mg tablets QD for a 4-week induction period followed by PF-06700841 30 mg tablets QD for a 20-week maintenance period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo tablets QD both matching for PF-06651600 and PF-06700841</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24</title>
          <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. Score range: 0-100%. Higher score indicates more severe disease. Change from baseline is defined as the baseline value minus the value at a specific visit. Positive change from baseline signifies an improvement. Baseline is defined as the last measurement prior to first dosing (Day 1).</description>
          <population>Number of Participants Analyzed: All randomized participants assigned to the study treatment. Number Analyzed: Number of Participants with observed data at Week 24</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.54" lower_limit="25.35" upper_limit="39.74"/>
                    <measurement group_id="O2" value="50.59" lower_limit="43.15" upper_limit="58.02"/>
                    <measurement group_id="O3" value="1.41" lower_limit="-6.03" upper_limit="8.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <p_value_desc>Hochberg P-value (one-sided)</p_value_desc>
            <method>Mixed Model Repeated Measure (MMRM)</method>
            <method_desc>MMRM contains fixed factors of treatment, week, baseline, treatment by week and treatment by baseline interaction and a random effect for subject.</method_desc>
            <param_type>Mean of Difference from Placebo</param_type>
            <param_value>31.14</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.25</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>18.78</ci_lower_limit>
            <ci_upper_limit>43.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <p_value_desc>Hochberg P-value (one-sided)</p_value_desc>
            <method>Mixed Model Repeated Measure (MMRM)</method>
            <method_desc>MMRM contains fixed factors of treatment, week, baseline, treatment by week and treatment by baseline interaction and a random effect for subject.</method_desc>
            <param_type>Mean of Difference from Placebo</param_type>
            <param_value>49.18</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.35</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>36.62</ci_lower_limit>
            <ci_upper_limit>61.74</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24 -AT/AU Participants</title>
        <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. Change from baseline is defined as the baseline value minus the value at a specific visit. Positive change from baseline implies an improvement. Alopecia totalis (AT): derived as SALT score = 100% at baseline only. Alopecia universalis (AU): derived as SALT score = 100% and both eyelash and eyebrow assessments were &quot;none&quot; at baseline.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Number of Participants Analyzed: AT/AU participants in the Full analysis set (FAS) was used. FAS consisted of all randomized participants, assigned to the randomized treatment regardless of what treatment, if any, was received. Number Analyzed: Number of participants with observed data at Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06651600-AT/AU</title>
            <description>AT/AU Participants received PF-06651600 200 mg once daily (QD) for 4 weeks induction period followed by PF-06651600 50 mg QD for a 20 weeks maintenance period.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841-AT/AU</title>
            <description>AT/AU Participants received PF-06700841 60 mg tablets QD for a 4-week induction period followed by PF-06700841 30 mg tablets QD for a 20-week maintenance period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo-AT/AU</title>
            <description>AT/AU Participants received placebo tablets QD both matching for PF-06651600 and PF-06700841.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24 -AT/AU Participants</title>
          <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. Change from baseline is defined as the baseline value minus the value at a specific visit. Positive change from baseline implies an improvement. Alopecia totalis (AT): derived as SALT score = 100% at baseline only. Alopecia universalis (AU): derived as SALT score = 100% and both eyelash and eyebrow assessments were &quot;none&quot; at baseline.</description>
          <population>Number of Participants Analyzed: AT/AU participants in the Full analysis set (FAS) was used. FAS consisted of all randomized participants, assigned to the randomized treatment regardless of what treatment, if any, was received. Number Analyzed: Number of participants with observed data at Week 24.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.59" lower_limit="15.24" upper_limit="39.94"/>
                    <measurement group_id="O2" value="48.42" lower_limit="36.38" upper_limit="60.47"/>
                    <measurement group_id="O3" value="1.81" lower_limit="-11.00" upper_limit="14.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0094</p_value>
            <method>Mixed Model Repeated Measure (MMRM)</method>
            <method_desc>MMRM contains fixed factors of treatment, week, baseline, treatment by week and treatment by baseline interaction and a random effect for subject.</method_desc>
            <param_type>Mean of Difference from Placebo</param_type>
            <param_value>25.78</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>10.64</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.98</ci_lower_limit>
            <ci_upper_limit>43.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Mixed Model Repeated Measure</method>
            <method_desc>MMRM contains fixed factors of treatment, week, baseline, treatment by week and treatment by baseline interaction and a random effect for subject.</method_desc>
            <param_type>Mean of Difference from Placebo</param_type>
            <param_value>46.61</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>10.51</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>29.02</ci_lower_limit>
            <ci_upper_limit>64.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-emergent Adverse Events (All-causality and Treatment-related) - Single-Blind Extension (SBE) Period</title>
        <description>An AE (non-serious and serious) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent Adverse Event (TEAE). Treatment-related TEAE were determined by investigators. Arms end with &quot;withdrawal Segment&quot; and &quot;retreatment segment&quot; described the same population while in different treatment segment .The reason why count on PF-06700841 differ by 1 participant is that 1 responder directly entered the retreatment segment and skipped the withdrawal segment.</description>
        <time_frame>Week 28 up to Week 52</time_frame>
        <population>The safety analysis set (SAS) was used , which was defined as all participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Non-responders on PF-06651600</title>
            <description>Participants initially treated with PF-06651600 in the Initial 24-Week Treatment Period and not responsive at Week 24 (ie, not achieving ≥30% improvement from baseline in SALT [SALT 30]) who were continually assigned to PF-06651600 in the Non-Responder Segment of the SBE Period</description>
          </group>
          <group group_id="O2">
            <title>Placebo Non-responders on PF-06651600</title>
            <description>Participants initially treated with placebo in the Initial 24-Week Treatment Period (1 participant receiving placebo in the Initial 24-Week Treatment Period was responsive at Week 24 but did not enter the SBE Period) who were assigned to PF-06651600 in the Non-Responder Segment of the SBE Period</description>
          </group>
          <group group_id="O3">
            <title>Active Non-responders on PF-06700841</title>
            <description>Participants initially treated with PF-06700841 in the Initial 24-Week Treatment Period and not responsive at Week 24 (ie, not achieving SALT 30) who were continually assigned to PF-06700841 in the Non-Responder Segment of the SBE Period</description>
          </group>
          <group group_id="O4">
            <title>Placebo Non-responders on PF-06700841</title>
            <description>Participants initially treated with placebo in the Initial 24-Week Treatment Period who were assigned to PF-06700841 in the Non-Responder Segment of the SBE Period</description>
          </group>
          <group group_id="O5">
            <title>Non-Retreated PF-06651600 Responders in the Withdrawal Segment</title>
            <description>Participants initially treated with PF-06651600 in the Initial 24-Week Treatment Period and responsive at Week 24 (ie, achieving SALT 30) who were assigned to placebo (withdrawal) without entering the Retreatment Segment of the SBE Period</description>
          </group>
          <group group_id="O6">
            <title>Retreated PF-06651600 Responders in the Withdrawal Segment</title>
            <description>Participants initially treated with PF-06651600 in the Initial 24-Week Treatment Period and responsive at Week 24 (ie, achieving SALT 30) who were assigned to placebo (withdrawal), and then entered the Retreatment Segment of the SBE Period to receive PF-06651600. This arm stands for retreated responders with TEAE within withdrawal Segment</description>
          </group>
          <group group_id="O7">
            <title>Non-Retreated PF-06700841 Responders in the Withdrawal Segment</title>
            <description>Participants initially treated with PF-06700841 in the Initial 24-Week Treatment Period and responsive at Week 24 (ie, achieving SALT 30) who were assigned to placebo (withdrawal) without entering the Retreatment Segment of the SBE Period</description>
          </group>
          <group group_id="O8">
            <title>Retreated PF-06700841 Responders in the Withdrawal Segment</title>
            <description>Participants initially treated with PF-06700841 in the Initial 24-Week Treatment Period and responsive at Week 24 (ie, achieving SALT 30) who were assigned to placebo (withdrawal), and then entered the Retreatment Segment of the SBE Period to receive PF-06700841. This arm stands for retreated responders with TEAE within withdrawal Segment</description>
          </group>
          <group group_id="O9">
            <title>Retreated PF-06651600 Responders in the Retreatment Segment</title>
            <description>Participants initially treated with PF-06651600 in the Initial 24-Week Treatment Period and responsive at Week 24 (ie, achieving SALT 30) who were assigned to placebo (withdrawal), and then entered the Retreatment Segment of the SBE Period to receive PF-06651600</description>
          </group>
          <group group_id="O10">
            <title>Retreated Responders on PF-06700841 in the Retreatment Segment</title>
            <description>Participants initially treated with PF-06700841 in the Initial 24-Week Treatment Period and responsive at Week 24 (ie, achieving SALT 30) who were assigned to placebo (withdrawal), and then entered the Retreatment Segment of the SBE Period to receive PF-06700841</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-emergent Adverse Events (All-causality and Treatment-related) - Single-Blind Extension (SBE) Period</title>
          <description>An AE (non-serious and serious) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent Adverse Event (TEAE). Treatment-related TEAE were determined by investigators. Arms end with &quot;withdrawal Segment&quot; and &quot;retreatment segment&quot; described the same population while in different treatment segment .The reason why count on PF-06700841 differ by 1 participant is that 1 responder directly entered the retreatment segment and skipped the withdrawal segment.</description>
          <population>The safety analysis set (SAS) was used , which was defined as all participants who received at least one dose of study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="14"/>
                <count group_id="O7" value="9"/>
                <count group_id="O8" value="14"/>
                <count group_id="O9" value="14"/>
                <count group_id="O10" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAE (All Causalities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="9"/>
                    <measurement group_id="O9" value="11"/>
                    <measurement group_id="O10" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE (Treatment Related)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-emergent Adverse Events (All-causality and Treatment-related) - Cross-Over Extension (COE) Period</title>
        <description>An AE (non-serious and serious) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent Adverse Event (TEAE). Treatment-related TEAE were determined by investigators.</description>
        <time_frame>COE day 1 up to end of study</time_frame>
        <population>The safety analysis set (SAS) was used , which was defined as all participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>COE-PF-06651600</title>
            <description>Participants not responsive to placebo or PF-06700841 at Week 24 in the Initial 24-Week Treatment Period and not responsive to PF-06700841 at Week 52 (ie, not achieving SALT 30) in the SBE Period who were assigned to PF-06651600 in the COE Period</description>
          </group>
          <group group_id="O2">
            <title>COE-PF-06700841</title>
            <description>Participants not responsive to placebo or PF-06651600 at Week 24 in the Initial 24-Week Treatment Period and not responsive to PF-06651600 at Week 52 (ie, not achieving SALT 30; except 1 PF-06651600 responder) in the SBE Period who were assigned to PF-06700841 in the COE Period</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-emergent Adverse Events (All-causality and Treatment-related) - Cross-Over Extension (COE) Period</title>
          <description>An AE (non-serious and serious) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent Adverse Event (TEAE). Treatment-related TEAE were determined by investigators.</description>
          <population>The safety analysis set (SAS) was used , which was defined as all participants who received at least one dose of study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAE (All Causalities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE (Treatment Related)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Laboratory Abnormalities During SBE Period</title>
        <description>Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology(Hemoglobin, Hematocrit, RBC count, Reticulocyte count, Platelet count, WBC count with differential, Total neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes); serum chemistry (BUN and Creatinine, Cystatin C, Creatine Phosphokinase, Glucose , Na+, K+, Cl ,Ca++, Total CO2, AST, ALT, Total Indirect &amp; Direct Bilirubin, Alkaline phosphatase, Uric acid, Albumin,Total protein, Fasting lipid Profile Panel; urinalysis(pH, Glucose, Protein, Nitrites, Leukocyte esterase, Microscopy culture);Other(HIV, HBsAg, HBcAb, HepB reflex (HbsAB), if applicable, HCVAb, Serum pregnancy test, Urine pregnancy test, FSH, QFT G or other IGRA, or PPD, EBV, CMV, HSV1, HSV2, VZV, Skin swab for herpetiform rash, Skin swab for potential drug related rash).Retest/discontinuation criteria are defined in Protocol Appendix 6.1 and 6.2 respectively.</description>
        <time_frame>Week 28 up to Week 52 for non-responders and responders in the withdrawal segment, AT day 1 up to AT Week 24 for retreatment segment (AT=active treatment)</time_frame>
        <population>The safety analysis set (SAS) was used. Arms end with &quot;withdrawal Segment&quot; and &quot;retreatment segment&quot; described the same population while in different treatment segment .The reason why count on PF-06700841 differ by 1 participant is that 1 responder skipped the withdrawal segment and entered the retreatment segment.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Non-responders on PF-06651600</title>
            <description>Participants initially treated with PF-06651600 in the Initial 24-Week Treatment Period and not responsive at Week 24 (ie, not achieving ≥30% improvement from baseline in SALT [SALT 30]) who were continually assigned to PF-06651600 in the Non-Responder Segment of the SBE Period</description>
          </group>
          <group group_id="O2">
            <title>Placebo Non-responders on PF-06651600</title>
            <description>Participants initially treated with placebo in the Initial 24-Week Treatment Period (1 participant receiving placebo in the Initial 24-Week Treatment Period was responsive at Week 24 but did not enter the SBE Period) who were assigned to PF-06651600 in the Non-Responder Segment of the SBE Period</description>
          </group>
          <group group_id="O3">
            <title>Active Non-responders on PF-06700841</title>
            <description>Participants initially treated with PF-06700841 in the Initial 24-Week Treatment Period and not responsive at Week 24 (ie, not achieving SALT 30) who were continually assigned to PF-06700841 in the Non-Responder Segment of the SBE Period</description>
          </group>
          <group group_id="O4">
            <title>Placebo Non-responders on PF-06700841</title>
            <description>Participants initially treated with placebo in the Initial 24-Week Treatment Period who were assigned to PF-06700841 in the Non-Responder Segment of the SBE Period</description>
          </group>
          <group group_id="O5">
            <title>Non-Retreated PF-06651600 Responders in the Withdrawal Segment</title>
            <description>Participants initially treated with PF-06651600 in the Initial 24-Week Treatment Period and responsive at Week 24 (ie, achieving SALT 30) who were assigned to placebo (withdrawal) without entering the Retreatment Segment of the SBE Period</description>
          </group>
          <group group_id="O6">
            <title>Retreated PF-06651600 Responders in the Withdrawal Segment</title>
            <description>Participants initially treated with PF-06651600 in the Initial 24-Week Treatment Period and responsive at Week 24 (ie, achieving SALT 30) who were assigned to placebo (withdrawal), and then entered the Retreatment Segment of the SBE Period to receive PF-06651600. This arm stands for retreated responders with TEAE within withdrawal Segment</description>
          </group>
          <group group_id="O7">
            <title>Non-Retreated PF-06700841 Responders in the Withdrawal Segment</title>
            <description>Participants initially treated with PF-06700841 in the Initial 24-Week Treatment Period and responsive at Week 24 (ie, achieving SALT 30) who were assigned to placebo (withdrawal) without entering the Retreatment Segment of the SBE Period</description>
          </group>
          <group group_id="O8">
            <title>Retreated PF-06700841 Responders in the Withdrawal Segment</title>
            <description>Participants initially treated with PF-06700841 in the Initial 24-Week Treatment Period and responsive at Week 24 (ie, achieving SALT 30) who were assigned to placebo (withdrawal), and then entered the Retreatment Segment of the SBE Period to receive PF-06700841. This arm stands for retreated responders with TEAE within withdrawal Segment</description>
          </group>
          <group group_id="O9">
            <title>Retreated PF-06651600 Responders in the Retreatment Segment</title>
            <description>Participants initially treated with PF-06651600 in the Initial 24-Week Treatment Period and responsive at Week 24 (ie, achieving SALT 30) who were assigned to placebo (withdrawal), and then entered the Retreatment Segment of the SBE Period to receive PF-06651600</description>
          </group>
          <group group_id="O10">
            <title>Retreated Responders on PF-06700841 in the Retreatment Segment</title>
            <description>Participants initially treated with PF-06700841 in the Initial 24-Week Treatment Period and responsive at Week 24 (ie, achieving SALT 30) who were assigned to placebo (withdrawal), and then entered the Retreatment Segment of the SBE Period to receive PF-06700841</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Laboratory Abnormalities During SBE Period</title>
          <description>Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology(Hemoglobin, Hematocrit, RBC count, Reticulocyte count, Platelet count, WBC count with differential, Total neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes); serum chemistry (BUN and Creatinine, Cystatin C, Creatine Phosphokinase, Glucose , Na+, K+, Cl ,Ca++, Total CO2, AST, ALT, Total Indirect &amp; Direct Bilirubin, Alkaline phosphatase, Uric acid, Albumin,Total protein, Fasting lipid Profile Panel; urinalysis(pH, Glucose, Protein, Nitrites, Leukocyte esterase, Microscopy culture);Other(HIV, HBsAg, HBcAb, HepB reflex (HbsAB), if applicable, HCVAb, Serum pregnancy test, Urine pregnancy test, FSH, QFT G or other IGRA, or PPD, EBV, CMV, HSV1, HSV2, VZV, Skin swab for herpetiform rash, Skin swab for potential drug related rash).Retest/discontinuation criteria are defined in Protocol Appendix 6.1 and 6.2 respectively.</description>
          <population>The safety analysis set (SAS) was used. Arms end with &quot;withdrawal Segment&quot; and &quot;retreatment segment&quot; described the same population while in different treatment segment .The reason why count on PF-06700841 differ by 1 participant is that 1 responder skipped the withdrawal segment and entered the retreatment segment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="14"/>
                <count group_id="O7" value="9"/>
                <count group_id="O8" value="14"/>
                <count group_id="O9" value="14"/>
                <count group_id="O10" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With abnormalities without regard to baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="10"/>
                    <measurement group_id="O9" value="11"/>
                    <measurement group_id="O10" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meeting Retest Criteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meeting Discontinuation Criteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Numbers of Participants With Specific Clinical Laboratory Abnormalities During COE Period</title>
        <description>Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology(Hemoglobin, Hematocrit, RBC count, Reticulocyte count, Platelet count, WBC count with differential, Total neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes); serum chemistry (BUN and Creatinine, Cystatin C, Creatine Phosphokinase, Glucose , Na+, K+, Cl ,Ca++, Total CO2, AST, ALT, Total Indirect &amp; Direct Bilirubin, Alkaline phosphatase, Uric acid, Albumin,Total protein, Fasting lipid Profile Panel; urinalysis(pH, Glucose, Protein, Nitrites, Leukocyte esterase, Microscopy culture);Other(HIV, HBsAg, HBcAb, HepB reflex (HbsAB), if applicable, HCVAb, Serum pregnancy test, Urine pregnancy test, FSH, QFT G or other IGRA, or PPD, EBV, CMV, HSV1, HSV2, VZV, Skin swab for herpetiform rash, Skin swab for potential drug related rash).Retest/discontinuation criteria are defined in Protocol Appendix 6.1 and 6.2 respectively.</description>
        <time_frame>COE day 1 up to end of study</time_frame>
        <population>All participants in safety analysis set (SAS) who received at least 1 dose of investigational product (PF-06651600, PF-06700841 or placebo) and had abnormal laboratory data in COE period.</population>
        <group_list>
          <group group_id="O1">
            <title>COE-PF-06651600</title>
            <description>Participants not responsive to placebo or PF-06700841 at Week 24 in the Initial 24-Week Treatment Period and not responsive to PF-06700841 at Week 52 (ie, not achieving SALT 30) in the SBE Period who were assigned to PF-06651600 in the COE Period</description>
          </group>
          <group group_id="O2">
            <title>COE-PF-06700841</title>
            <description>Participants not responsive to placebo or PF-06651600 at Week 24 in the Initial 24-Week Treatment Period and not responsive to PF-06651600 at Week 52 (ie, not achieving SALT 30; except 1 PF-06651600 responder) in the SBE Period who were assigned to PF-06700841 in the COE Period</description>
          </group>
        </group_list>
        <measure>
          <title>Numbers of Participants With Specific Clinical Laboratory Abnormalities During COE Period</title>
          <description>Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology(Hemoglobin, Hematocrit, RBC count, Reticulocyte count, Platelet count, WBC count with differential, Total neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes); serum chemistry (BUN and Creatinine, Cystatin C, Creatine Phosphokinase, Glucose , Na+, K+, Cl ,Ca++, Total CO2, AST, ALT, Total Indirect &amp; Direct Bilirubin, Alkaline phosphatase, Uric acid, Albumin,Total protein, Fasting lipid Profile Panel; urinalysis(pH, Glucose, Protein, Nitrites, Leukocyte esterase, Microscopy culture);Other(HIV, HBsAg, HBcAb, HepB reflex (HbsAB), if applicable, HCVAb, Serum pregnancy test, Urine pregnancy test, FSH, QFT G or other IGRA, or PPD, EBV, CMV, HSV1, HSV2, VZV, Skin swab for herpetiform rash, Skin swab for potential drug related rash).Retest/discontinuation criteria are defined in Protocol Appendix 6.1 and 6.2 respectively.</description>
          <population>All participants in safety analysis set (SAS) who received at least 1 dose of investigational product (PF-06651600, PF-06700841 or placebo) and had abnormal laboratory data in COE period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With abnormalities without regard to baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meeting Retest Criteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meeting Discontinuation Criteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving SALT 30 at Week 24</title>
        <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 30 response is a 30% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The 90% CI was calculated using Chan and Zhang method.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>All participants in the Full analysis set (FAS) was used and have observed data at Week 24. FAS consisted of all randomized participants, assigned to the randomized treatment regardless of what treatment, if any, was received.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06651600</title>
            <description>Participants received PF-06651600 200 mg QD for 4 weeks induction period followed by PF-06651600 50 mg QD for a 20 weeks maintenance period.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841</title>
            <description>Participants received PF-06700841 60 mg tablets QD for a 4-week induction period followed by PF-06700841 30 mg tablets QD for a 20-week maintenance period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo tablets QD both matching for PF-06651600 and PF-06700841</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving SALT 30 at Week 24</title>
          <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 30 response is a 30% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The 90% CI was calculated using Chan and Zhang method.</description>
          <population>All participants in the Full analysis set (FAS) was used and have observed data at Week 24. FAS consisted of all randomized participants, assigned to the randomized treatment regardless of what treatment, if any, was received.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="37.6" upper_limit="62.4"/>
                    <measurement group_id="O2" value="63.8" lower_limit="51.3" upper_limit="74.9"/>
                    <measurement group_id="O3" value="2.1" lower_limit="0.2" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Chan and Zhang method</method>
            <param_type>Difference in Percentage from Placebo</param_type>
            <param_value>47.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>34.2</ci_lower_limit>
            <ci_upper_limit>60.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Chan and Zhang method</method>
            <param_type>Difference in Percentage from Placebo</param_type>
            <param_value>61.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>48.2</ci_lower_limit>
            <ci_upper_limit>73.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Severity of Alopecia Tool (SALT) Across Time (Treatment Period)</title>
        <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. The SALT score can vary from 0 to 100% with higher score indicates more severe disease. Baseline is defined as the last measurement prior to first dosing (Day 1). Change from baseline is defined as the baseline value minus the value at a specific visit. Positive change from baseline implies an improvement. Least Square Mean and 90% Confidence Interval of Arms (PF-06651600 and PF-06700841) are the Least Square Mean and 90% Confidence Interval for difference from placebo respectively.</description>
        <time_frame>Baseline, Weeks 2,4,6,8,12,16,20,24</time_frame>
        <population>&quot;Number of participants analyzed&quot;: All randomized participants assigned to the study treatment. &quot;Number analyzed&quot; : Number of participants with observed data for each specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06651600</title>
            <description>Participants received PF-06651600 200 mg QD for 4 weeks induction period followed by PF-06651600 50 mg QD for a 20 weeks maintenance period.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841</title>
            <description>Participants received PF-06700841 60 mg tablets QD for a 4-week induction period followed by PF-06700841 30 mg tablets QD for a 20-week maintenance period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo tablets QD both matching for PF-06651600 and PF-06700841</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Severity of Alopecia Tool (SALT) Across Time (Treatment Period)</title>
          <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. The SALT score can vary from 0 to 100% with higher score indicates more severe disease. Baseline is defined as the last measurement prior to first dosing (Day 1). Change from baseline is defined as the baseline value minus the value at a specific visit. Positive change from baseline implies an improvement. Least Square Mean and 90% Confidence Interval of Arms (PF-06651600 and PF-06700841) are the Least Square Mean and 90% Confidence Interval for difference from placebo respectively.</description>
          <population>&quot;Number of participants analyzed&quot;: All randomized participants assigned to the study treatment. &quot;Number analyzed&quot; : Number of participants with observed data for each specified time point.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.74" lower_limit="-2.06" upper_limit="0.59"/>
                    <measurement group_id="O2" value="-0.93" lower_limit="-2.27" upper_limit="0.40"/>
                    <measurement group_id="O3" value="1.18" lower_limit="0.23" upper_limit="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.93" lower_limit="-1.32" upper_limit="7.17"/>
                    <measurement group_id="O2" value="7.70" lower_limit="3.43" upper_limit="11.97"/>
                    <measurement group_id="O3" value="0.85" lower_limit="-2.20" upper_limit="3.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.44" lower_limit="5.42" upper_limit="19.45"/>
                    <measurement group_id="O2" value="19.37" lower_limit="12.29" upper_limit="26.45"/>
                    <measurement group_id="O3" value="1.32" lower_limit="-3.72" upper_limit="6.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.49" lower_limit="9.57" upper_limit="27.41"/>
                    <measurement group_id="O2" value="29.30" lower_limit="20.28" upper_limit="38.32"/>
                    <measurement group_id="O3" value="1.77" lower_limit="-4.63" upper_limit="8.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.49" lower_limit="14.90" upper_limit="34.09"/>
                    <measurement group_id="O2" value="36.57" lower_limit="26.86" upper_limit="46.29"/>
                    <measurement group_id="O3" value="1.62" lower_limit="-5.26" upper_limit="8.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.59" lower_limit="17.67" upper_limit="37.50"/>
                    <measurement group_id="O2" value="41.16" lower_limit="31.11" upper_limit="51.22"/>
                    <measurement group_id="O3" value="1.61" lower_limit="-5.49" upper_limit="8.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.32" lower_limit="19.06" upper_limit="39.57"/>
                    <measurement group_id="O2" value="45.55" lower_limit="35.14" upper_limit="55.97"/>
                    <measurement group_id="O3" value="1.62" lower_limit="-5.73" upper_limit="8.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.14" lower_limit="20.79" upper_limit="41.49"/>
                    <measurement group_id="O2" value="49.18" lower_limit="38.66" upper_limit="59.70"/>
                    <measurement group_id="O3" value="1.41" lower_limit="-6.03" upper_limit="8.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Severity of Alopecia Tool (SALT) Across Time (Treatment Period)</title>
        <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. The SALT score can vary from 0 to 100% with higher score indicates more severe disease. Baseline is defined as the last measurement prior to first dosing (Day 1). Percent change from baseline is defined as SALT baseline value minus SALT value at a specific visit divided by baseline and multiplying by 100. Positive change from baseline implies an improvement. Least Square Mean and 90% Confidence Interval of Arms (PF-06651600 and PF-06700841) are the Least Square Mean and 90% Confidence Interval for difference from placebo respectively.</description>
        <time_frame>Baseline, Weeks 2,4,6,8,12,16,20,24</time_frame>
        <population>&quot;Number of participants analyzed&quot;: All randomized participants assigned to the study treatment. &quot;Number analyzed&quot; : Number of participants with observed data for each specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06651600</title>
            <description>Participants received PF-06651600 200 mg QD for 4 weeks induction period followed by PF-06651600 50 mg QD for a 20 weeks maintenance period.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841</title>
            <description>Participants received PF-06700841 60 mg tablets QD for a 4-week induction period followed by PF-06700841 30 mg tablets QD for a 20-week maintenance period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo tablets QD both matching for PF-06651600 and PF-06700841</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Severity of Alopecia Tool (SALT) Across Time (Treatment Period)</title>
          <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. The SALT score can vary from 0 to 100% with higher score indicates more severe disease. Baseline is defined as the last measurement prior to first dosing (Day 1). Percent change from baseline is defined as SALT baseline value minus SALT value at a specific visit divided by baseline and multiplying by 100. Positive change from baseline implies an improvement. Least Square Mean and 90% Confidence Interval of Arms (PF-06651600 and PF-06700841) are the Least Square Mean and 90% Confidence Interval for difference from placebo respectively.</description>
          <population>&quot;Number of participants analyzed&quot;: All randomized participants assigned to the study treatment. &quot;Number analyzed&quot; : Number of participants with observed data for each specified time point.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.76" lower_limit="-2.26" upper_limit="0.75"/>
                    <measurement group_id="O2" value="-1.13" lower_limit="-2.64" upper_limit="0.39"/>
                    <measurement group_id="O3" value="1.26" lower_limit="0.18" upper_limit="2.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.99" lower_limit="-0.86" upper_limit="8.83"/>
                    <measurement group_id="O2" value="9.70" lower_limit="4.83" upper_limit="14.57"/>
                    <measurement group_id="O3" value="0.53" lower_limit="-2.96" upper_limit="4.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.88" lower_limit="7.84" upper_limit="23.91"/>
                    <measurement group_id="O2" value="22.88" lower_limit="14.77" upper_limit="30.99"/>
                    <measurement group_id="O3" value="1.02" lower_limit="-4.75" upper_limit="6.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.22" lower_limit="13.15" upper_limit="33.29"/>
                    <measurement group_id="O2" value="34.78" lower_limit="24.59" upper_limit="44.96"/>
                    <measurement group_id="O3" value="1.31" lower_limit="-5.91" upper_limit="8.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.99" lower_limit="19.93" upper_limit="42.05"/>
                    <measurement group_id="O2" value="44.17" lower_limit="32.97" upper_limit="55.37"/>
                    <measurement group_id="O3" value="0.99" lower_limit="-6.94" upper_limit="8.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.14" lower_limit="23.65" upper_limit="46.62"/>
                    <measurement group_id="O2" value="49.99" lower_limit="38.35" upper_limit="61.64"/>
                    <measurement group_id="O3" value="0.86" lower_limit="-7.38" upper_limit="9.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.31" lower_limit="25.37" upper_limit="49.25"/>
                    <measurement group_id="O2" value="55.46" lower_limit="43.34" upper_limit="67.58"/>
                    <measurement group_id="O3" value="0.91" lower_limit="-7.65" upper_limit="9.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.67" lower_limit="27.66" upper_limit="51.68"/>
                    <measurement group_id="O2" value="59.71" lower_limit="47.51" upper_limit="71.92"/>
                    <measurement group_id="O3" value="0.43" lower_limit="-8.20" upper_limit="9.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving SALT 30 Across Time (Treatment Period)</title>
        <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 30 response is a 30% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method.</description>
        <time_frame>Baseline, Weeks 2,4,6,8,12,16,20,24</time_frame>
        <population>All participants in the Full analysis set (FAS) was used. FAS consisted of all randomized participants, assigned to the randomized treatment regardless of what treatment, if any, was received.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06651600</title>
            <description>Participants received PF-06651600 200 mg QD for 4 weeks induction period followed by PF-06651600 50 mg QD for a 20 weeks maintenance period.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841</title>
            <description>Participants received PF-06700841 60 mg tablets QD for a 4-week induction period followed by PF-06700841 30 mg tablets QD for a 20-week maintenance period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo tablets QD both matching for PF-06651600 and PF-06700841</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving SALT 30 Across Time (Treatment Period)</title>
          <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 30 response is a 30% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method.</description>
          <population>All participants in the Full analysis set (FAS) was used. FAS consisted of all randomized participants, assigned to the randomized treatment regardless of what treatment, if any, was received.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" lower_limit="-9.7" upper_limit="3.7"/>
                    <measurement group_id="O2" value="-2.1" lower_limit="-9.7" upper_limit="3.5"/>
                    <measurement group_id="O3" value="2.1" lower_limit="0.2" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" lower_limit="-2.3" upper_limit="15.8"/>
                    <measurement group_id="O2" value="12.8" lower_limit="3.0" upper_limit="24.0"/>
                    <measurement group_id="O3" value="2.1" lower_limit="0.2" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7" lower_limit="7.0" upper_limit="31.0"/>
                    <measurement group_id="O2" value="27.7" lower_limit="15.4" upper_limit="40.4"/>
                    <measurement group_id="O3" value="2.1" lower_limit="0.2" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="13.2" upper_limit="37.4"/>
                    <measurement group_id="O2" value="38.3" lower_limit="25.8" upper_limit="51.4"/>
                    <measurement group_id="O3" value="2.1" lower_limit="0.2" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.5" lower_limit="26.4" upper_limit="52.6"/>
                    <measurement group_id="O2" value="48.9" lower_limit="35.8" upper_limit="61.8"/>
                    <measurement group_id="O3" value="2.1" lower_limit="0.2" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.8" lower_limit="32.2" upper_limit="58.7"/>
                    <measurement group_id="O2" value="55.3" lower_limit="42.0" upper_limit="67.8"/>
                    <measurement group_id="O3" value="2.1" lower_limit="0.2" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.9" lower_limit="34.2" upper_limit="60.7"/>
                    <measurement group_id="O2" value="59.6" lower_limit="46.3" upper_limit="71.7"/>
                    <measurement group_id="O3" value="2.1" lower_limit="0.2" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.9" lower_limit="34.2" upper_limit="60.7"/>
                    <measurement group_id="O2" value="61.7" lower_limit="48.2" upper_limit="73.6"/>
                    <measurement group_id="O3" value="2.1" lower_limit="0.2" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving SALT 50 Across Time (Treatment Period)</title>
        <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 50 response is a 50% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method.</description>
        <time_frame>Baseline, Weeks 2,4,6,8,12,16,20,24</time_frame>
        <population>All participants in the Full analysis set (FAS) was used. FAS consisted of all randomized participants, assigned to the randomized treatment regardless of what treatment, if any, was received.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06651600</title>
            <description>Participants received PF-06651600 200 mg QD for 4 weeks induction period followed by PF-06651600 50 mg QD for a 20 weeks maintenance period.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841</title>
            <description>Participants received PF-06700841 60 mg tablets QD for a 4-week induction period followed by PF-06700841 30 mg tablets QD for a 20-week maintenance period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo tablets QD both matching for PF-06651600 and PF-06700841</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving SALT 50 Across Time (Treatment Period)</title>
          <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 50 response is a 50% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method.</description>
          <population>All participants in the Full analysis set (FAS) was used. FAS consisted of all randomized participants, assigned to the randomized treatment regardless of what treatment, if any, was received.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-6.2" upper_limit="6.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-6.2" upper_limit="6.2"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-6.2" upper_limit="6.1"/>
                    <measurement group_id="O2" value="10.6" lower_limit="3.6" upper_limit="21.1"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" lower_limit="1.1" upper_limit="21.1"/>
                    <measurement group_id="O2" value="17.0" lower_limit="6.5" upper_limit="28.8"/>
                    <measurement group_id="O3" value="2.1" lower_limit="0.2" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7" lower_limit="7.0" upper_limit="31.0"/>
                    <measurement group_id="O2" value="29.8" lower_limit="17.2" upper_limit="42.7"/>
                    <measurement group_id="O3" value="2.1" lower_limit="0.2" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.0" lower_limit="15.0" upper_limit="39.6"/>
                    <measurement group_id="O2" value="36.2" lower_limit="23.8" upper_limit="49.2"/>
                    <measurement group_id="O3" value="2.1" lower_limit="0.2" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="20.3" upper_limit="46.2"/>
                    <measurement group_id="O2" value="40.4" lower_limit="27.8" upper_limit="53.5"/>
                    <measurement group_id="O3" value="2.1" lower_limit="0.2" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="20.3" upper_limit="46.2"/>
                    <measurement group_id="O2" value="46.8" lower_limit="33.8" upper_limit="59.8"/>
                    <measurement group_id="O3" value="2.1" lower_limit="0.2" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5" lower_limit="24.5" upper_limit="50.6"/>
                    <measurement group_id="O2" value="51.1" lower_limit="37.9" upper_limit="63.8"/>
                    <measurement group_id="O3" value="2.1" lower_limit="0.2" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving SALT 75 Across Time (Treatment Period)</title>
        <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 75 response is a 75% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method.</description>
        <time_frame>Baseline, Weeks 2,4,6,8,12,16,20,24</time_frame>
        <population>All participants in the Full analysis set (FAS) was used. FAS consisted of all randomized participants, assigned to the randomized treatment regardless of what treatment, if any, was received.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06651600</title>
            <description>Participants received PF-06651600 200 mg QD for 4 weeks induction period followed by PF-06651600 50 mg QD for a 20 weeks maintenance period.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841</title>
            <description>Participants received PF-06700841 60 mg tablets QD for a 4-week induction period followed by PF-06700841 30 mg tablets QD for a 20-week maintenance period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo tablets QD both matching for PF-06651600 and PF-06700841</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving SALT 75 Across Time (Treatment Period)</title>
          <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 75 response is a 75% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method.</description>
          <population>All participants in the Full analysis set (FAS) was used. FAS consisted of all randomized participants, assigned to the randomized treatment regardless of what treatment, if any, was received.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-6.2" upper_limit="6.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-6.2" upper_limit="6.2"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-6.2" upper_limit="6.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-6.2" upper_limit="6.2"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" lower_limit="1.8" upper_limit="18.1"/>
                    <measurement group_id="O2" value="10.6" lower_limit="3.6" upper_limit="21.1"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" lower_limit="2.8" upper_limit="23.6"/>
                    <measurement group_id="O2" value="23.4" lower_limit="11.8" upper_limit="36.2"/>
                    <measurement group_id="O3" value="2.1" lower_limit="0.2" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.6" lower_limit="6.3" upper_limit="28.6"/>
                    <measurement group_id="O2" value="27.7" lower_limit="15.4" upper_limit="40.4"/>
                    <measurement group_id="O3" value="2.1" lower_limit="0.2" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8" lower_limit="8.6" upper_limit="33.0"/>
                    <measurement group_id="O2" value="31.9" lower_limit="19.0" upper_limit="44.9"/>
                    <measurement group_id="O3" value="2.1" lower_limit="0.2" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="13.2" upper_limit="37.4"/>
                    <measurement group_id="O2" value="38.3" lower_limit="25.8" upper_limit="51.4"/>
                    <measurement group_id="O3" value="2.1" lower_limit="0.2" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.0" lower_limit="15.0" upper_limit="39.6"/>
                    <measurement group_id="O2" value="40.4" lower_limit="27.8" upper_limit="53.5"/>
                    <measurement group_id="O3" value="2.1" lower_limit="0.2" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving SALT 90 Across Time (Treatment Period)</title>
        <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 90 response is a 90% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method.</description>
        <time_frame>Baseline, Weeks 2,4,6,8,12,16,20,24</time_frame>
        <population>All participants in the Full analysis set (FAS) was used. FAS consisted of all randomized participants, assigned to the randomized treatment regardless of what treatment, if any, was received.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06651600</title>
            <description>Participants received PF-06651600 200 mg QD for 4 weeks induction period followed by PF-06651600 50 mg QD for a 20 weeks maintenance period.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841</title>
            <description>Participants received PF-06700841 60 mg tablets QD for a 4-week induction period followed by PF-06700841 30 mg tablets QD for a 20-week maintenance period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo tablets QD both matching for PF-06651600 and PF-06700841</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving SALT 90 Across Time (Treatment Period)</title>
          <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 90 response is a 90% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method.</description>
          <population>All participants in the Full analysis set (FAS) was used. FAS consisted of all randomized participants, assigned to the randomized treatment regardless of what treatment, if any, was received.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-6.2" upper_limit="6.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-6.2" upper_limit="6.2"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-6.2" upper_limit="6.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-6.2" upper_limit="6.2"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-6.2" upper_limit="6.1"/>
                    <measurement group_id="O2" value="6.4" lower_limit="0.2" upper_limit="15.7"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="-2.0" upper_limit="12.5"/>
                    <measurement group_id="O2" value="12.8" lower_limit="5.2" upper_limit="23.6"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" lower_limit="3.4" upper_limit="20.7"/>
                    <measurement group_id="O2" value="25.5" lower_limit="15.4" upper_limit="38.1"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" lower_limit="8.6" upper_limit="27.7"/>
                    <measurement group_id="O2" value="27.7" lower_limit="17.2" upper_limit="40.3"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7" lower_limit="7.0" upper_limit="31.0"/>
                    <measurement group_id="O2" value="29.8" lower_limit="17.2" upper_limit="42.7"/>
                    <measurement group_id="O3" value="2.1" lower_limit="0.2" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="15.1" upper_limit="37.3"/>
                    <measurement group_id="O2" value="34.0" lower_limit="22.7" upper_limit="47.0"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving SALT 100 Across Time (Treatment Period)</title>
        <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 100 response is a 100% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method.</description>
        <time_frame>Baseline, Weeks 2,4,6,8,12,16,20,24</time_frame>
        <population>All participants in the Full analysis set (FAS) was used. FAS consisted of all randomized participants, assigned to the randomized treatment regardless of what treatment, if any, was received.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06651600</title>
            <description>Participants received PF-06651600 200 mg QD for 4 weeks induction period followed by PF-06651600 50 mg QD for a 20 weeks maintenance period.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841</title>
            <description>Participants received PF-06700841 60 mg tablets QD for a 4-week induction period followed by PF-06700841 30 mg tablets QD for a 20-week maintenance period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo tablets QD both matching for PF-06651600 and PF-06700841</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving SALT 100 Across Time (Treatment Period)</title>
          <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 100 response is a 100% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method.</description>
          <population>All participants in the Full analysis set (FAS) was used. FAS consisted of all randomized participants, assigned to the randomized treatment regardless of what treatment, if any, was received.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-6.2" upper_limit="6.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-6.2" upper_limit="6.2"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-6.2" upper_limit="6.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-6.2" upper_limit="6.2"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-6.2" upper_limit="6.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-6.2" upper_limit="6.2"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-6.2" upper_limit="6.1"/>
                    <measurement group_id="O2" value="2.1" lower_limit="-3.5" upper_limit="9.7"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="-3.8" upper_limit="9.5"/>
                    <measurement group_id="O2" value="6.4" lower_limit="0.2" upper_limit="15.7"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="-3.8" upper_limit="9.5"/>
                    <measurement group_id="O2" value="8.5" lower_limit="1.9" upper_limit="18.4"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="-2.0" upper_limit="12.5"/>
                    <measurement group_id="O2" value="12.8" lower_limit="5.2" upper_limit="23.6"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" lower_limit="5.1" upper_limit="23.2"/>
                    <measurement group_id="O2" value="12.8" lower_limit="5.2" upper_limit="23.6"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With the IGA Score Change (Treatment Period)</title>
        <description>The clinical evaluator of alopecia areata (AA) will perform an assessment of the overall improvement of AA and assign an Investigator Global Assessment (IGA) score(ranging from 0 to 5) with higher score representing higher regrowth rate. Baseline is defined as the last measurement prior to first dosing (Day 1).</description>
        <time_frame>baseline, Week 2,4,6,8,12,16,20,24</time_frame>
        <population>&quot;Number of participants analyzed&quot;: All randomized participants assigned to the study treatment. &quot;Number analyzed&quot; : Number of participants with observed data for each specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06651600</title>
            <description>Participants received PF-06651600 200 mg QD for 4 weeks induction period followed by PF-06651600 50 mg QD for a 20 weeks maintenance period.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841</title>
            <description>Participants received PF-06700841 60 mg tablets QD for a 4-week induction period followed by PF-06700841 30 mg tablets QD for a 20-week maintenance period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo tablets QD both matching for PF-06651600 and PF-06700841</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With the IGA Score Change (Treatment Period)</title>
          <description>The clinical evaluator of alopecia areata (AA) will perform an assessment of the overall improvement of AA and assign an Investigator Global Assessment (IGA) score(ranging from 0 to 5) with higher score representing higher regrowth rate. Baseline is defined as the last measurement prior to first dosing (Day 1).</description>
          <population>&quot;Number of participants analyzed&quot;: All randomized participants assigned to the study treatment. &quot;Number analyzed&quot; : Number of participants with observed data for each specified time point.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0 (NO CHANGE OR FURTHER LOSS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1 (1-24% REGROWTH)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 (25-49% REGROWTH)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 (50-74% REGROWTH)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4 (75-99% REGROWTH)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5 (100% REGROWTH)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0 (NO CHANGE OR FURTHER LOSS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1 (1-24% REGROWTH)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 (25-49% REGROWTH)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 (50-74% REGROWTH)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4 (75-99% REGROWTH)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5 (100% REGROWTH)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0 (NO CHANGE OR FURTHER LOSS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1 (1-24% REGROWTH)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 (25-49% REGROWTH)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 (50-74% REGROWTH)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4 (75-99% REGROWTH)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5 (100% REGROWTH)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0 (NO CHANGE OR FURTHER LOSS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1 (1-24% REGROWTH)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 (25-49% REGROWTH)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 (50-74% REGROWTH)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4 (75-99% REGROWTH)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5 (100% REGROWTH)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0 (NO CHANGE OR FURTHER LOSS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1 (1-24% REGROWTH)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 (25-49% REGROWTH)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 (50-74% REGROWTH)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4 (75-99% REGROWTH)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5 (100% REGROWTH)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0 (NO CHANGE OR FURTHER LOSS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1 (1-24% REGROWTH)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 (25-49% REGROWTH)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 (50-74% REGROWTH)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4 (75-99% REGROWTH)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5 (100% REGROWTH)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0 (NO CHANGE OR FURTHER LOSS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1 (1-24% REGROWTH)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 (25-49% REGROWTH)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 (50-74% REGROWTH)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4 (75-99% REGROWTH)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5 (100% REGROWTH)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0 (NO CHANGE OR FURTHER LOSS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1 (1-24% REGROWTH)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 (25-49% REGROWTH)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 (50-74% REGROWTH)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4 (75-99% REGROWTH)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5 (100% REGROWTH)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0 (NO CHANGE OR FURTHER LOSS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1 (1-24% REGROWTH)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 (25-49% REGROWTH)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 (50-74% REGROWTH)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4 (75-99% REGROWTH)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5 (100% REGROWTH)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-emergent Adverse Events (All-causality and Treatment-related) - Treatment Period</title>
        <description>An AE (non-serious and serious) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent Adverse Event (TEAE). Treatment-related TEAE were determined by investigators.</description>
        <time_frame>baseline up to Week 24</time_frame>
        <population>All participants who received at least 1 dose of investigational product (PF-06651600, PF-06700841 or placebo) in Treatment Period.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06651600</title>
            <description>Participants received PF-06651600 200 mg QD for 4 weeks induction period followed by PF-06651600 50 mg QD for a 20 weeks maintenance period.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841</title>
            <description>Participants received PF-06700841 60 mg tablets QD for a 4-week induction period followed by PF-06700841 30 mg tablets QD for a 20-week maintenance period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo tablets QD both matching for PF-06651600 and PF-06700841</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-emergent Adverse Events (All-causality and Treatment-related) - Treatment Period</title>
          <description>An AE (non-serious and serious) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent Adverse Event (TEAE). Treatment-related TEAE were determined by investigators.</description>
          <population>All participants who received at least 1 dose of investigational product (PF-06651600, PF-06700841 or placebo) in Treatment Period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAE (All Causalities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE (Treatment Related)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Laboratory Abnormalities During Treatment Period</title>
        <description>Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology(Hemoglobin, Hematocrit, RBC count, Reticulocyte count, Platelet count, WBC count with differential, Total neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes); serum chemistry (BUN and Creatinine, Cystatin C, Creatine Phosphokinase, Glucose , Na+, K+, Cl ,Ca++, Total CO2, AST, ALT, Total Indirect &amp; Direct Bilirubin, Alkaline phosphatase, Uric acid, Albumin,Total protein, Fasting lipid Profile Panel; urinalysis(pH, Glucose, Protein, Nitrites, Leukocyte esterase, Microscopy culture);Other(HIV, HBsAg, HBcAb, HepB reflex (HbsAB), if applicable, HCVAb, Serum pregnancy test, Urine pregnancy test, FSH, QFT G or other IGRA, or PPD, EBV, CMV, HSV1, HSV2, VZV, Skin swab for herpetiform rash, Skin swab for potential drug related rash).Retest/discontinuation criteria are defined in Protocol Appendix 6.1 and 6.2 respectively.</description>
        <time_frame>Baseline up to Week 24</time_frame>
        <population>All participants in safety analysis set (SAS) who received at least 1 dose of investigational product (PF-06651600, PF-06700841 or placebo) and had abnormal laboratory data in treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06651600</title>
            <description>Participants received PF-06651600 200 mg QD for 4 weeks induction period followed by PF-06651600 50 mg QD for a 20 weeks maintenance period.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841</title>
            <description>Participants received PF-06700841 60 mg tablets QD for a 4-week induction period followed by PF-06700841 30 mg tablets QD for a 20-week maintenance period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo tablets QD both matching for PF-06651600 and PF-06700841</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Laboratory Abnormalities During Treatment Period</title>
          <description>Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology(Hemoglobin, Hematocrit, RBC count, Reticulocyte count, Platelet count, WBC count with differential, Total neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes); serum chemistry (BUN and Creatinine, Cystatin C, Creatine Phosphokinase, Glucose , Na+, K+, Cl ,Ca++, Total CO2, AST, ALT, Total Indirect &amp; Direct Bilirubin, Alkaline phosphatase, Uric acid, Albumin,Total protein, Fasting lipid Profile Panel; urinalysis(pH, Glucose, Protein, Nitrites, Leukocyte esterase, Microscopy culture);Other(HIV, HBsAg, HBcAb, HepB reflex (HbsAB), if applicable, HCVAb, Serum pregnancy test, Urine pregnancy test, FSH, QFT G or other IGRA, or PPD, EBV, CMV, HSV1, HSV2, VZV, Skin swab for herpetiform rash, Skin swab for potential drug related rash).Retest/discontinuation criteria are defined in Protocol Appendix 6.1 and 6.2 respectively.</description>
          <population>All participants in safety analysis set (SAS) who received at least 1 dose of investigational product (PF-06651600, PF-06700841 or placebo) and had abnormal laboratory data in treatment period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With abnormalities without regard to baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meeting Safety Criteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meeting Retest Criteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meeting Discontinuation Criteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Achieve the Retreatment Criteria During the Withdrawal/Retreatment Part of the Extension Period Among Subjects Who Achieved Primary Endpoint at Week 24 (SBE Period)</title>
        <description>Time to re-treatment (weeks) = (date of re-treatment criteria met - date at Week 24 +1)/7. The calendar time to retreatment was calculated. Baseline is defined as Week 24 measurement. The duration in Drug Holiday #1 (ranging from 2-6 weeks) is counted in the Kaplan-Meier analysis. One subject directly entered the re-treatment period and hence is censored at baseline in the Kaplan-Meier analysis.</description>
        <time_frame>Week 24 up to Week 52</time_frame>
        <population>All randomized participants who were responsive at Week 24 (ie, achieving SALT30 at Week 24).All randomized participants who were responsive at Week 24 (ie, achieving SALT30 at Week 24).</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06651600 Responders</title>
            <description>Participants received PF-06651600 200 mg once daily (QD) for 4 weeks induction period followed by PF-06651600 50 mg QD for a 20 weeks maintenance period responsive at Week 24 (ie, achieving SALT 30) who were assigned to placebo (withdrawal)</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 Responders</title>
            <description>Participants received PF-06700841 60 mg tablets QD for a 4-week induction period followed by PF-06700841 30 mg tablets QD for a 20-week maintenance period and responsive at Week 24 (ie, achieving SALT 30) who were assigned to placebo (withdrawal)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Achieve the Retreatment Criteria During the Withdrawal/Retreatment Part of the Extension Period Among Subjects Who Achieved Primary Endpoint at Week 24 (SBE Period)</title>
          <description>Time to re-treatment (weeks) = (date of re-treatment criteria met - date at Week 24 +1)/7. The calendar time to retreatment was calculated. Baseline is defined as Week 24 measurement. The duration in Drug Holiday #1 (ranging from 2-6 weeks) is counted in the Kaplan-Meier analysis. One subject directly entered the re-treatment period and hence is censored at baseline in the Kaplan-Meier analysis.</description>
          <population>All randomized participants who were responsive at Week 24 (ie, achieving SALT30 at Week 24).All randomized participants who were responsive at Week 24 (ie, achieving SALT30 at Week 24).</population>
          <units>Weeks</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Q1 time to retreatment (25th percentile of time)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" lower_limit="4.3" upper_limit="12.6"/>
                    <measurement group_id="O2" value="11.0" lower_limit="4.1" upper_limit="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median time to retreatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1" lower_limit="10.1" upper_limit="20.3"/>
                    <measurement group_id="O2" value="24.1" lower_limit="14.6" upper_limit="NA">NA indicates not estimable. The withdrawal segment is not lengthy enough to observe upper limit of the 95% CI for the median time to retreatment (ie. 50% of participants meeting the criterion).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q3 time to retreatment (75th percentile of time)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.1" lower_limit="16.1" upper_limit="NA">NA indicates not estimable. The withdrawal segment is not lengthy enough to observe upper limit of the 95% CI for the Q3 time to retreatment (ie. 75% of participants meeting the criterion).</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="24.3" upper_limit="NA">NA indicates not estimable. The withdrawal segment is not lengthy enough to observe Q3 time to retreatment (ie. 75% of participants meeting the criterion) and corresponding upper limit of the 95% CI.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SALT Across Time (SBE Period)</title>
        <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. The SALT score can vary from 0 to 100% with higher score indicates more severe disease. Baseline is defined as the last measurement prior to first dosing (Day 1). Change from baseline is defined as the baseline value minus the value at a specific visit. Positive change from baseline implies an improvement. Least Square Mean and 90% confidence interval in this outcome measurement is the LSM and 90%CI for difference from initial 24-week treatment period placebo respectively.</description>
        <time_frame>Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)</time_frame>
        <population>Number of Participants Analyzed: All randomized participants assigned to the study treatment. Number Analyzed: Number of Participants with observed data. 6 groups of participants were each compared with initial 24-week treatment period placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Non-responders on PF-06651600</title>
            <description>Participants initially treated with PF-06651600 in the Initial 24-Week Treatment Period and not responsive at Week 24 (ie, not achieving ≥30% improvement from baseline in SALT [SALT 30]) who were continually assigned to PF-06651600 in the Non-Responder Segment of the SBE Period</description>
          </group>
          <group group_id="O2">
            <title>Active Non-responders on PF-06700841</title>
            <description>Participants initially treated with PF-06700841 in the Initial 24-Week Treatment Period and not responsive at Week 24 (ie, not achieving SALT 30) who were continually assigned to PF-06700841 in the Non-Responder Segment of the SBE Period</description>
          </group>
          <group group_id="O3">
            <title>Placebo Non-responders on PF-06651600</title>
            <description>Participants initially treated with placebo in the Initial 24-Week Treatment Period (1 participant receiving placebo in the Initial 24-Week Treatment Period was responsive at Week 24 but did not enter the SBE Period) who were assigned to PF-06651600 in the Non-Responder Segment of the SBE Period</description>
          </group>
          <group group_id="O4">
            <title>Placebo Non-responders on PF-06700841</title>
            <description>Participants initially treated with placebo in the Initial 24-Week Treatment Period who were assigned to PF-06700841 in the Non-Responder Segment of the SBE Period</description>
          </group>
          <group group_id="O5">
            <title>Retreated PF-06651600 Responders in the Retreatment Segment</title>
            <description>Participants initially treated with PF-06651600 in the Initial 24-Week Treatment Period and responsive at Week 24 (ie, achieving SALT 30) who were assigned to placebo (withdrawal), and then entered the Retreatment Segment of the SBE Period to receive PF-06651600</description>
          </group>
          <group group_id="O6">
            <title>Retreated Responders on PF-06700841 in the Retreatment Segment</title>
            <description>Participants initially treated with PF-06700841 in the Initial 24-Week Treatment Period and responsive at Week 24 (ie, achieving SALT 30) who were assigned to placebo (withdrawal), and then entered the Retreatment Segment of the SBE Period to receive PF-06700841</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SALT Across Time (SBE Period)</title>
          <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. The SALT score can vary from 0 to 100% with higher score indicates more severe disease. Baseline is defined as the last measurement prior to first dosing (Day 1). Change from baseline is defined as the baseline value minus the value at a specific visit. Positive change from baseline implies an improvement. Least Square Mean and 90% confidence interval in this outcome measurement is the LSM and 90%CI for difference from initial 24-week treatment period placebo respectively.</description>
          <population>Number of Participants Analyzed: All randomized participants assigned to the study treatment. Number Analyzed: Number of Participants with observed data. 6 groups of participants were each compared with initial 24-week treatment period placebo.</population>
          <units>unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 30/ AT Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.76" lower_limit="-4.47" upper_limit="7.99"/>
                    <measurement group_id="O2" value="0.09" lower_limit="-9.83" upper_limit="10.01"/>
                    <measurement group_id="O3" value="2.99" lower_limit="-4.56" upper_limit="10.54"/>
                    <measurement group_id="O4" value="-0.31" lower_limit="-9.53" upper_limit="8.92"/>
                    <measurement group_id="O5" value="25.04" lower_limit="15.01" upper_limit="35.08"/>
                    <measurement group_id="O6" value="19.83" lower_limit="10.00" upper_limit="29.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32/ AT Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.85" lower_limit="-4.37" upper_limit="8.07"/>
                    <measurement group_id="O2" value="2.22" lower_limit="-7.78" upper_limit="12.21"/>
                    <measurement group_id="O3" value="3.37" lower_limit="-4.06" upper_limit="10.79"/>
                    <measurement group_id="O4" value="3.71" lower_limit="-4.93" upper_limit="12.35"/>
                    <measurement group_id="O5" value="27.63" lower_limit="17.67" upper_limit="37.59"/>
                    <measurement group_id="O6" value="15.66" lower_limit="5.82" upper_limit="25.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 34/ AT Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.80" lower_limit="-4.42" upper_limit="8.02"/>
                    <measurement group_id="O2" value="3.16" lower_limit="-6.90" upper_limit="13.23"/>
                    <measurement group_id="O3" value="10.16" lower_limit="2.55" upper_limit="17.77"/>
                    <measurement group_id="O4" value="24.67" lower_limit="16.00" upper_limit="33.34"/>
                    <measurement group_id="O5" value="33.78" lower_limit="23.72" upper_limit="43.83"/>
                    <measurement group_id="O6" value="20.09" lower_limit="10.17" upper_limit="30.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36/ AT Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="11"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.16" lower_limit="-4.09" upper_limit="8.40"/>
                    <measurement group_id="O2" value="3.01" lower_limit="-7.12" upper_limit="13.14"/>
                    <measurement group_id="O3" value="8.93" lower_limit="1.34" upper_limit="16.52"/>
                    <measurement group_id="O4" value="42.32" lower_limit="33.37" upper_limit="51.28"/>
                    <measurement group_id="O5" value="38.80" lower_limit="28.75" upper_limit="48.84"/>
                    <measurement group_id="O6" value="27.35" lower_limit="17.42" upper_limit="37.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40/ AT Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.35" lower_limit="-2.91" upper_limit="9.61"/>
                    <measurement group_id="O2" value="3.19" lower_limit="-7.00" upper_limit="13.38"/>
                    <measurement group_id="O3" value="18.30" lower_limit="10.73" upper_limit="25.86"/>
                    <measurement group_id="O4" value="50.27" lower_limit="41.65" upper_limit="58.90"/>
                    <measurement group_id="O5" value="43.70" lower_limit="33.58" upper_limit="53.82"/>
                    <measurement group_id="O6" value="39.28" lower_limit="29.36" upper_limit="49.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44/ AT Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="11"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.41" lower_limit="-2.84" upper_limit="9.67"/>
                    <measurement group_id="O2" value="3.12" lower_limit="-7.19" upper_limit="13.43"/>
                    <measurement group_id="O3" value="25.71" lower_limit="17.70" upper_limit="33.72"/>
                    <measurement group_id="O4" value="54.69" lower_limit="45.73" upper_limit="63.64"/>
                    <measurement group_id="O5" value="48.93" lower_limit="38.59" upper_limit="59.27"/>
                    <measurement group_id="O6" value="50.58" lower_limit="40.48" upper_limit="60.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48/ AT Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.70" lower_limit="-1.57" upper_limit="10.97"/>
                    <measurement group_id="O2" value="2.97" lower_limit="-7.39" upper_limit="13.34"/>
                    <measurement group_id="O3" value="25.28" lower_limit="17.42" upper_limit="33.13"/>
                    <measurement group_id="O4" value="62.45" lower_limit="53.13" upper_limit="71.77"/>
                    <measurement group_id="O5" value="53.74" lower_limit="43.39" upper_limit="64.09"/>
                    <measurement group_id="O6" value="53.79" lower_limit="43.57" upper_limit="64.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52/ AT Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="11"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.06" lower_limit="0.75" upper_limit="13.38"/>
                    <measurement group_id="O2" value="3.01" lower_limit="-7.47" upper_limit="13.49"/>
                    <measurement group_id="O3" value="28.88" lower_limit="20.20" upper_limit="37.56"/>
                    <measurement group_id="O4" value="58.53" lower_limit="49.42" upper_limit="67.63"/>
                    <measurement group_id="O5" value="55.94" lower_limit="45.42" upper_limit="66.46"/>
                    <measurement group_id="O6" value="58.37" lower_limit="48.11" upper_limit="68.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving SALT 30 Across Time (SBE Period)</title>
        <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 30 response is a 30% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method.</description>
        <time_frame>Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)</time_frame>
        <population>All participants in the Full analysis set (FAS) was used. FAS consisted of all randomized participants, assigned to the randomized treatment regardless of what treatment, if any, was received.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Non-responders on PF-06651600</title>
            <description>Participants initially treated with PF-06651600 in the Initial 24-Week Treatment Period and not responsive at Week 24 (ie, not achieving ≥30% improvement from baseline in SALT [SALT 30]) who were continually assigned to PF-06651600 in the Non-Responder Segment of the SBE Period</description>
          </group>
          <group group_id="O2">
            <title>Active Non-responders on PF-06700841</title>
            <description>Participants initially treated with PF-06700841 in the Initial 24-Week Treatment Period and not responsive at Week 24 (ie, not achieving SALT 30) who were continually assigned to PF-06700841 in the Non-Responder Segment of the SBE Period</description>
          </group>
          <group group_id="O3">
            <title>Placebo Non-responders on PF-06651600</title>
            <description>Participants initially treated with placebo in the Initial 24-Week Treatment Period (1 participant receiving placebo in the Initial 24-Week Treatment Period was responsive at Week 24 but did not enter the SBE Period) who were assigned to PF-06651600 in the Non-Responder Segment of the SBE Period</description>
          </group>
          <group group_id="O4">
            <title>Placebo Non-responders on PF-06700841</title>
            <description>Participants initially treated with placebo in the Initial 24-Week Treatment Period who were assigned to PF-06700841 in the Non-Responder Segment of the SBE Period</description>
          </group>
          <group group_id="O5">
            <title>Retreated PF-06651600 Responders in the Retreatment Segment</title>
            <description>Participants initially treated with PF-06651600 in the Initial 24-Week Treatment Period and responsive at Week 24 (ie, achieving SALT 30) who were assigned to placebo (withdrawal), and then entered the Retreatment Segment of the SBE Period to receive PF-06651600</description>
          </group>
          <group group_id="O6">
            <title>Retreated Responders on PF-06700841 in the Retreatment Segment</title>
            <description>Participants initially treated with PF-06700841 in the Initial 24-Week Treatment Period and responsive at Week 24 (ie, achieving SALT 30) who were assigned to placebo (withdrawal), and then entered the Retreatment Segment of the SBE Period to receive PF-06700841</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving SALT 30 Across Time (SBE Period)</title>
          <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 30 response is a 30% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method.</description>
          <population>All participants in the Full analysis set (FAS) was used. FAS consisted of all randomized participants, assigned to the randomized treatment regardless of what treatment, if any, was received.</population>
          <units>percent of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 30/ AT Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" lower_limit="-5.3" upper_limit="23.0"/>
                    <measurement group_id="O2" value="-2.1" lower_limit="-10.9" upper_limit="40.0"/>
                    <measurement group_id="O3" value="3.8" lower_limit="-5.5" upper_limit="21.6"/>
                    <measurement group_id="O4" value="-2.1" lower_limit="-9.7" upper_limit="18.9"/>
                    <measurement group_id="O5" value="47.9" lower_limit="25.3" upper_limit="70.0"/>
                    <measurement group_id="O6" value="31.2" lower_limit="12.8" upper_limit="54.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32/ AT Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" lower_limit="-5.3" upper_limit="23.0"/>
                    <measurement group_id="O2" value="-2.1" lower_limit="-10.9" upper_limit="40.0"/>
                    <measurement group_id="O3" value="9.6" lower_limit="-2.4" upper_limit="30.2"/>
                    <measurement group_id="O4" value="14.5" lower_limit="0.4" upper_limit="39.4"/>
                    <measurement group_id="O5" value="62.2" lower_limit="38.2" upper_limit="81.5"/>
                    <measurement group_id="O6" value="11.2" lower_limit="-1.0" upper_limit="33.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 34/ AT Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" lower_limit="-5.3" upper_limit="23.0"/>
                    <measurement group_id="O2" value="-2.1" lower_limit="-10.9" upper_limit="40.0"/>
                    <measurement group_id="O3" value="21.4" lower_limit="4.8" upper_limit="43.2"/>
                    <measurement group_id="O4" value="31.2" lower_limit="10.9" upper_limit="57.0"/>
                    <measurement group_id="O5" value="69.3" lower_limit="45.3" upper_limit="86.5"/>
                    <measurement group_id="O6" value="31.2" lower_limit="12.8" upper_limit="54.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36/ AT Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" lower_limit="-5.3" upper_limit="23.0"/>
                    <measurement group_id="O2" value="-2.1" lower_limit="-10.9" upper_limit="40.0"/>
                    <measurement group_id="O3" value="21.4" lower_limit="4.8" upper_limit="43.2"/>
                    <measurement group_id="O4" value="56.2" lower_limit="30.8" upper_limit="78.2"/>
                    <measurement group_id="O5" value="69.3" lower_limit="45.3" upper_limit="86.5"/>
                    <measurement group_id="O6" value="44.5" lower_limit="23.2" upper_limit="66.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40/ AT Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" lower_limit="-1.5" upper_limit="31.8"/>
                    <measurement group_id="O2" value="-2.1" lower_limit="-10.9" upper_limit="40.0"/>
                    <measurement group_id="O3" value="27.3" lower_limit="8.5" upper_limit="49.6"/>
                    <measurement group_id="O4" value="81.2" lower_limit="55.6" upper_limit="94.4"/>
                    <measurement group_id="O5" value="62.2" lower_limit="38.2" upper_limit="81.5"/>
                    <measurement group_id="O6" value="51.2" lower_limit="28.9" upper_limit="72.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44/ AT Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" lower_limit="-1.5" upper_limit="31.8"/>
                    <measurement group_id="O2" value="-2.1" lower_limit="-10.9" upper_limit="40.0"/>
                    <measurement group_id="O3" value="33.2" lower_limit="15.2" upper_limit="54.5"/>
                    <measurement group_id="O4" value="64.5" lower_limit="38.4" upper_limit="84.5"/>
                    <measurement group_id="O5" value="62.2" lower_limit="38.2" upper_limit="81.5"/>
                    <measurement group_id="O6" value="51.2" lower_limit="28.9" upper_limit="72.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48/ AT Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" lower_limit="-1.5" upper_limit="31.8"/>
                    <measurement group_id="O2" value="-2.1" lower_limit="-10.9" upper_limit="40.0"/>
                    <measurement group_id="O3" value="39.0" lower_limit="20.0" upper_limit="60.1"/>
                    <measurement group_id="O4" value="64.5" lower_limit="38.4" upper_limit="84.5"/>
                    <measurement group_id="O5" value="69.3" lower_limit="45.3" upper_limit="86.5"/>
                    <measurement group_id="O6" value="51.2" lower_limit="28.9" upper_limit="72.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52/ AT Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" lower_limit="-1.5" upper_limit="31.8"/>
                    <measurement group_id="O2" value="-2.1" lower_limit="-10.9" upper_limit="40.0"/>
                    <measurement group_id="O3" value="27.3" lower_limit="8.5" upper_limit="49.6"/>
                    <measurement group_id="O4" value="64.5" lower_limit="38.4" upper_limit="84.5"/>
                    <measurement group_id="O5" value="55.0" lower_limit="31.6" upper_limit="76.0"/>
                    <measurement group_id="O6" value="51.2" lower_limit="28.9" upper_limit="72.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving SALT 50 Across Time (SBE Period)</title>
        <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 50 response is a 50% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method.</description>
        <time_frame>Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)</time_frame>
        <population>All participants in the Full analysis set (FAS) was used. FAS consisted of all randomized participants, assigned to the randomized treatment regardless of what treatment, if any, was received.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Non-responders on PF-06651600</title>
            <description>Participants initially treated with PF-06651600 in the Initial 24-Week Treatment Period and not responsive at Week 24 (ie, not achieving ≥30% improvement from baseline in SALT [SALT 30]) who were continually assigned to PF-06651600 in the Non-Responder Segment of the SBE Period</description>
          </group>
          <group group_id="O2">
            <title>Active Non-responders on PF-06700841</title>
            <description>Participants initially treated with PF-06700841 in the Initial 24-Week Treatment Period and not responsive at Week 24 (ie, not achieving SALT 30) who were continually assigned to PF-06700841 in the Non-Responder Segment of the SBE Period</description>
          </group>
          <group group_id="O3">
            <title>Placebo Non-responders on PF-06651600</title>
            <description>Participants initially treated with placebo in the Initial 24-Week Treatment Period (1 participant receiving placebo in the Initial 24-Week Treatment Period was responsive at Week 24 but did not enter the SBE Period) who were assigned to PF-06651600 in the Non-Responder Segment of the SBE Period</description>
          </group>
          <group group_id="O4">
            <title>Placebo Non-responders on PF-06700841</title>
            <description>Participants initially treated with placebo in the Initial 24-Week Treatment Period who were assigned to PF-06700841 in the Non-Responder Segment of the SBE Period</description>
          </group>
          <group group_id="O5">
            <title>Retreated PF-06651600 Responders in the Retreatment Segment</title>
            <description>Participants initially treated with PF-06651600 in the Initial 24-Week Treatment Period and responsive at Week 24 (ie, achieving SALT 30) who were assigned to placebo (withdrawal), and then entered the Retreatment Segment of the SBE Period to receive PF-06651600</description>
          </group>
          <group group_id="O6">
            <title>Retreated Responders on PF-06700841 in the Retreatment Segment</title>
            <description>Participants initially treated with PF-06700841 in the Initial 24-Week Treatment Period and responsive at Week 24 (ie, achieving SALT 30) who were assigned to placebo (withdrawal), and then entered the Retreatment Segment of the SBE Period to receive PF-06700841</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving SALT 50 Across Time (SBE Period)</title>
          <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 50 response is a 50% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method.</description>
          <population>All participants in the Full analysis set (FAS) was used. FAS consisted of all randomized participants, assigned to the randomized treatment regardless of what treatment, if any, was received.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 30/ AT Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-6.3" upper_limit="17.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-7.4" upper_limit="45.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-6.2" upper_limit="16.2"/>
                    <measurement group_id="O4" value="0.0" lower_limit="-6.3" upper_limit="22.1"/>
                    <measurement group_id="O5" value="14.3" lower_limit="2.4" upper_limit="38.5"/>
                    <measurement group_id="O6" value="20.0" lower_limit="5.7" upper_limit="44.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32/ AT Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-6.3" upper_limit="17.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-7.4" upper_limit="45.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-6.2" upper_limit="16.2"/>
                    <measurement group_id="O4" value="0.0" lower_limit="-6.3" upper_limit="22.1"/>
                    <measurement group_id="O5" value="21.4" lower_limit="6.1" upper_limit="46.6"/>
                    <measurement group_id="O6" value="6.7" lower_limit="-2.1" upper_limit="27.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 34/ AT Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" lower_limit="-9.7" upper_limit="13.8"/>
                    <measurement group_id="O2" value="-2.1" lower_limit="-10.9" upper_limit="40.0"/>
                    <measurement group_id="O3" value="9.6" lower_limit="-2.4" upper_limit="30.2"/>
                    <measurement group_id="O4" value="31.2" lower_limit="10.9" upper_limit="57.0"/>
                    <measurement group_id="O5" value="26.4" lower_limit="6.1" upper_limit="50.0"/>
                    <measurement group_id="O6" value="11.2" lower_limit="-1.0" upper_limit="33.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36/ AT Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" lower_limit="-9.7" upper_limit="13.8"/>
                    <measurement group_id="O2" value="-2.1" lower_limit="-10.9" upper_limit="40.0"/>
                    <measurement group_id="O3" value="3.8" lower_limit="-5.5" upper_limit="21.6"/>
                    <measurement group_id="O4" value="56.2" lower_limit="30.8" upper_limit="78.2"/>
                    <measurement group_id="O5" value="33.6" lower_limit="14.1" upper_limit="57.2"/>
                    <measurement group_id="O6" value="24.5" lower_limit="5.6" upper_limit="47.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40/ AT Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" lower_limit="-9.7" upper_limit="13.8"/>
                    <measurement group_id="O2" value="-2.1" lower_limit="-10.9" upper_limit="40.0"/>
                    <measurement group_id="O3" value="15.5" lower_limit="1.1" upper_limit="36.8"/>
                    <measurement group_id="O4" value="56.2" lower_limit="30.8" upper_limit="78.2"/>
                    <measurement group_id="O5" value="47.9" lower_limit="25.3" upper_limit="70.0"/>
                    <measurement group_id="O6" value="44.5" lower_limit="23.2" upper_limit="66.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44/ AT Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" lower_limit="-9.7" upper_limit="13.8"/>
                    <measurement group_id="O2" value="-2.1" lower_limit="-10.9" upper_limit="40.0"/>
                    <measurement group_id="O3" value="21.4" lower_limit="4.8" upper_limit="43.2"/>
                    <measurement group_id="O4" value="64.5" lower_limit="38.4" upper_limit="84.5"/>
                    <measurement group_id="O5" value="47.9" lower_limit="25.3" upper_limit="70.0"/>
                    <measurement group_id="O6" value="44.5" lower_limit="23.2" upper_limit="66.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48/ AT Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" lower_limit="-5.3" upper_limit="23.0"/>
                    <measurement group_id="O2" value="-2.1" lower_limit="-10.9" upper_limit="40.0"/>
                    <measurement group_id="O3" value="27.3" lower_limit="8.5" upper_limit="49.6"/>
                    <measurement group_id="O4" value="64.5" lower_limit="38.4" upper_limit="84.5"/>
                    <measurement group_id="O5" value="47.9" lower_limit="25.3" upper_limit="70.0"/>
                    <measurement group_id="O6" value="37.9" lower_limit="17.9" upper_limit="60.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52/ AT Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" lower_limit="-5.3" upper_limit="23.0"/>
                    <measurement group_id="O2" value="-2.1" lower_limit="-10.9" upper_limit="40.0"/>
                    <measurement group_id="O3" value="27.3" lower_limit="8.5" upper_limit="49.6"/>
                    <measurement group_id="O4" value="64.5" lower_limit="38.4" upper_limit="84.5"/>
                    <measurement group_id="O5" value="47.9" lower_limit="25.3" upper_limit="70.0"/>
                    <measurement group_id="O6" value="44.5" lower_limit="23.2" upper_limit="66.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving SALT 75 Across Time (SBE Period)</title>
        <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 75 response is a 75% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method.</description>
        <time_frame>Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)</time_frame>
        <population>All participants in the Full analysis set (FAS) was used. FAS consisted of all randomized participants, assigned to the randomized treatment regardless of what treatment, if any, was received.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Non-responders on PF-06651600</title>
            <description>Participants initially treated with PF-06651600 in the Initial 24-Week Treatment Period and not responsive at Week 24 (ie, not achieving ≥30% improvement from baseline in SALT [SALT 30]) who were continually assigned to PF-06651600 in the Non-Responder Segment of the SBE Period</description>
          </group>
          <group group_id="O2">
            <title>Active Non-responders on PF-06700841</title>
            <description>Participants initially treated with PF-06700841 in the Initial 24-Week Treatment Period and not responsive at Week 24 (ie, not achieving SALT 30) who were continually assigned to PF-06700841 in the Non-Responder Segment of the SBE Period</description>
          </group>
          <group group_id="O3">
            <title>Placebo Non-responders on PF-06651600</title>
            <description>Participants initially treated with placebo in the Initial 24-Week Treatment Period (1 participant receiving placebo in the Initial 24-Week Treatment Period was responsive at Week 24 but did not enter the SBE Period) who were assigned to PF-06651600 in the Non-Responder Segment of the SBE Period</description>
          </group>
          <group group_id="O4">
            <title>Placebo Non-responders on PF-06700841</title>
            <description>Participants initially treated with placebo in the Initial 24-Week Treatment Period who were assigned to PF-06700841 in the Non-Responder Segment of the SBE Period</description>
          </group>
          <group group_id="O5">
            <title>Retreated PF-06651600 Responders in the Retreatment Segment</title>
            <description>Participants initially treated with PF-06651600 in the Initial 24-Week Treatment Period and responsive at Week 24 (ie, achieving SALT 30) who were assigned to placebo (withdrawal), and then entered the Retreatment Segment of the SBE Period to receive PF-06651600</description>
          </group>
          <group group_id="O6">
            <title>Retreated Responders on PF-06700841 in the Retreatment Segment</title>
            <description>Participants initially treated with PF-06700841 in the Initial 24-Week Treatment Period and responsive at Week 24 (ie, achieving SALT 30) who were assigned to placebo (withdrawal), and then entered the Retreatment Segment of the SBE Period to receive PF-06700841</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving SALT 75 Across Time (SBE Period)</title>
          <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 75 response is a 75% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method.</description>
          <population>All participants in the Full analysis set (FAS) was used. FAS consisted of all randomized participants, assigned to the randomized treatment regardless of what treatment, if any, was received.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 30/ AT Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-6.3" upper_limit="17.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-7.4" upper_limit="45.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-6.2" upper_limit="16.2"/>
                    <measurement group_id="O4" value="0.0" lower_limit="-6.3" upper_limit="22.1"/>
                    <measurement group_id="O5" value="0.0" lower_limit="-6.8" upper_limit="19.3"/>
                    <measurement group_id="O6" value="0.0" lower_limit="-6.6" upper_limit="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32/ AT Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-6.3" upper_limit="17.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-7.4" upper_limit="45.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-6.2" upper_limit="16.2"/>
                    <measurement group_id="O4" value="0.0" lower_limit="-6.3" upper_limit="22.1"/>
                    <measurement group_id="O5" value="7.1" lower_limit="-1.9" upper_limit="29.7"/>
                    <measurement group_id="O6" value="0.0" lower_limit="-6.6" upper_limit="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 34/ AT Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-6.3" upper_limit="17.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-7.4" upper_limit="45.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-6.2" upper_limit="16.2"/>
                    <measurement group_id="O4" value="8.3" lower_limit="-1.5" upper_limit="33.9"/>
                    <measurement group_id="O5" value="14.3" lower_limit="2.4" upper_limit="38.5"/>
                    <measurement group_id="O6" value="6.7" lower_limit="-2.1" upper_limit="27.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36/ AT Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" lower_limit="-9.7" upper_limit="13.8"/>
                    <measurement group_id="O2" value="-2.1" lower_limit="-10.9" upper_limit="40.0"/>
                    <measurement group_id="O3" value="-2.1" lower_limit="-9.7" upper_limit="13.3"/>
                    <measurement group_id="O4" value="22.9" lower_limit="2.8" upper_limit="48.7"/>
                    <measurement group_id="O5" value="26.4" lower_limit="6.1" upper_limit="50.0"/>
                    <measurement group_id="O6" value="17.9" lower_limit="1.8" upper_limit="40.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40/ AT Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" lower_limit="-9.7" upper_limit="13.8"/>
                    <measurement group_id="O2" value="-2.1" lower_limit="-10.9" upper_limit="40.0"/>
                    <measurement group_id="O3" value="3.8" lower_limit="-5.5" upper_limit="21.6"/>
                    <measurement group_id="O4" value="39.5" lower_limit="17.0" upper_limit="64.5"/>
                    <measurement group_id="O5" value="26.4" lower_limit="6.1" upper_limit="50.0"/>
                    <measurement group_id="O6" value="31.2" lower_limit="12.8" upper_limit="54.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44/ AT Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" lower_limit="-9.7" upper_limit="13.8"/>
                    <measurement group_id="O2" value="-2.1" lower_limit="-10.9" upper_limit="40.0"/>
                    <measurement group_id="O3" value="15.5" lower_limit="1.1" upper_limit="36.8"/>
                    <measurement group_id="O4" value="56.2" lower_limit="30.8" upper_limit="78.2"/>
                    <measurement group_id="O5" value="26.4" lower_limit="6.1" upper_limit="50.0"/>
                    <measurement group_id="O6" value="37.9" lower_limit="17.9" upper_limit="60.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48/ AT Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" lower_limit="-9.7" upper_limit="13.8"/>
                    <measurement group_id="O2" value="-2.1" lower_limit="-10.9" upper_limit="40.0"/>
                    <measurement group_id="O3" value="15.5" lower_limit="1.1" upper_limit="36.8"/>
                    <measurement group_id="O4" value="64.5" lower_limit="38.4" upper_limit="84.5"/>
                    <measurement group_id="O5" value="28.6" lower_limit="6.1" upper_limit="50.0"/>
                    <measurement group_id="O6" value="37.9" lower_limit="17.9" upper_limit="60.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52/ AT Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" lower_limit="-5.3" upper_limit="23.0"/>
                    <measurement group_id="O2" value="-2.1" lower_limit="-10.9" upper_limit="40.0"/>
                    <measurement group_id="O3" value="27.3" lower_limit="8.5" upper_limit="49.6"/>
                    <measurement group_id="O4" value="64.5" lower_limit="38.4" upper_limit="84.5"/>
                    <measurement group_id="O5" value="33.6" lower_limit="14.1" upper_limit="57.2"/>
                    <measurement group_id="O6" value="37.9" lower_limit="17.9" upper_limit="60.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving SALT 90 Across Time (SBE Period)</title>
        <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 90 response is a 90% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method.</description>
        <time_frame>Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)</time_frame>
        <population>All participants in the Full analysis set (FAS) was used. FAS consisted of all randomized participants, assigned to the randomized treatment regardless of what treatment, if any, was received.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Non-responders on PF-06651600</title>
            <description>Participants initially treated with PF-06651600 in the Initial 24-Week Treatment Period and not responsive at Week 24 (ie, not achieving ≥30% improvement from baseline in SALT [SALT 30]) who were continually assigned to PF-06651600 in the Non-Responder Segment of the SBE Period</description>
          </group>
          <group group_id="O2">
            <title>Active Non-responders on PF-06700841</title>
            <description>Participants initially treated with PF-06700841 in the Initial 24-Week Treatment Period and not responsive at Week 24 (ie, not achieving SALT 30) who were continually assigned to PF-06700841 in the Non-Responder Segment of the SBE Period</description>
          </group>
          <group group_id="O3">
            <title>Placebo Non-responders on PF-06651600</title>
            <description>Participants initially treated with placebo in the Initial 24-Week Treatment Period (1 participant receiving placebo in the Initial 24-Week Treatment Period was responsive at Week 24 but did not enter the SBE Period) who were assigned to PF-06651600 in the Non-Responder Segment of the SBE Period</description>
          </group>
          <group group_id="O4">
            <title>Placebo Non-responders on PF-06700841</title>
            <description>Participants initially treated with placebo in the Initial 24-Week Treatment Period who were assigned to PF-06700841 in the Non-Responder Segment of the SBE Period</description>
          </group>
          <group group_id="O5">
            <title>Retreated PF-06651600 Responders in the Retreatment Segment</title>
            <description>Participants initially treated with PF-06651600 in the Initial 24-Week Treatment Period and responsive at Week 24 (ie, achieving SALT 30) who were assigned to placebo (withdrawal), and then entered the Retreatment Segment of the SBE Period to receive PF-06651600</description>
          </group>
          <group group_id="O6">
            <title>Retreated Responders on PF-06700841 in the Retreatment Segment</title>
            <description>Participants initially treated with PF-06700841 in the Initial 24-Week Treatment Period and responsive at Week 24 (ie, achieving SALT 30) who were assigned to placebo (withdrawal), and then entered the Retreatment Segment of the SBE Period to receive PF-06700841</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving SALT 90 Across Time (SBE Period)</title>
          <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 90 response is a 90% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method.</description>
          <population>All participants in the Full analysis set (FAS) was used. FAS consisted of all randomized participants, assigned to the randomized treatment regardless of what treatment, if any, was received.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 30/ AT Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-6.3" upper_limit="17.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-7.4" upper_limit="45.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-6.2" upper_limit="16.2"/>
                    <measurement group_id="O4" value="0.0" lower_limit="-6.3" upper_limit="22.1"/>
                    <measurement group_id="O5" value="0.0" lower_limit="-6.8" upper_limit="19.3"/>
                    <measurement group_id="O6" value="0.0" lower_limit="-6.6" upper_limit="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32/ AT Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-6.3" upper_limit="17.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-7.4" upper_limit="45.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-6.2" upper_limit="16.2"/>
                    <measurement group_id="O4" value="0.0" lower_limit="-6.3" upper_limit="22.1"/>
                    <measurement group_id="O5" value="0.0" lower_limit="-6.8" upper_limit="19.3"/>
                    <measurement group_id="O6" value="0.0" lower_limit="-6.6" upper_limit="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 34/ AT Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-6.3" upper_limit="17.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-7.4" upper_limit="45.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-6.2" upper_limit="16.2"/>
                    <measurement group_id="O4" value="0.0" lower_limit="-6.3" upper_limit="22.1"/>
                    <measurement group_id="O5" value="0.0" lower_limit="-6.8" upper_limit="19.3"/>
                    <measurement group_id="O6" value="0.0" lower_limit="-6.6" upper_limit="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36/ AT Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-6.3" upper_limit="17.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-7.4" upper_limit="45.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-6.2" upper_limit="16.2"/>
                    <measurement group_id="O4" value="8.3" lower_limit="-1.5" upper_limit="33.9"/>
                    <measurement group_id="O5" value="7.1" lower_limit="-1.9" upper_limit="29.7"/>
                    <measurement group_id="O6" value="6.7" lower_limit="-2.1" upper_limit="27.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40/ AT Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-6.3" upper_limit="17.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-7.4" upper_limit="45.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-6.2" upper_limit="16.2"/>
                    <measurement group_id="O4" value="25.0" lower_limit="7.2" upper_limit="52.7"/>
                    <measurement group_id="O5" value="14.3" lower_limit="2.4" upper_limit="38.5"/>
                    <measurement group_id="O6" value="13.3" lower_limit="2.1" upper_limit="36.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44/ AT Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-6.3" upper_limit="17.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-7.4" upper_limit="45.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-6.2" upper_limit="16.2"/>
                    <measurement group_id="O4" value="33.3" lower_limit="12.3" upper_limit="60.9"/>
                    <measurement group_id="O5" value="21.4" lower_limit="6.1" upper_limit="46.6"/>
                    <measurement group_id="O6" value="20.0" lower_limit="5.7" upper_limit="44.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48/ AT Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" lower_limit="-9.7" upper_limit="13.8"/>
                    <measurement group_id="O2" value="-2.1" lower_limit="-10.9" upper_limit="40.0"/>
                    <measurement group_id="O3" value="3.8" lower_limit="-5.5" upper_limit="21.6"/>
                    <measurement group_id="O4" value="47.9" lower_limit="23.6" upper_limit="71.6"/>
                    <measurement group_id="O5" value="26.4" lower_limit="6.1" upper_limit="50.0"/>
                    <measurement group_id="O6" value="24.5" lower_limit="5.6" upper_limit="47.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52/ AT Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-6.3" upper_limit="17.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-7.4" upper_limit="45.1"/>
                    <measurement group_id="O3" value="17.6" lower_limit="5.0" upper_limit="39.6"/>
                    <measurement group_id="O4" value="50.0" lower_limit="24.5" upper_limit="75.5"/>
                    <measurement group_id="O5" value="28.6" lower_limit="10.4" upper_limit="54.0"/>
                    <measurement group_id="O6" value="40.0" lower_limit="19.1" upper_limit="64.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving SALT 100 Across Time (SBE Period)</title>
        <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 100 response is a 100% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method.</description>
        <time_frame>Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)</time_frame>
        <population>All participants in the Full analysis set (FAS) was used. FAS consisted of all randomized participants, assigned to the randomized treatment regardless of what treatment, if any, was received.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Non-responders on PF-06651600</title>
            <description>Participants initially treated with PF-06651600 in the Initial 24-Week Treatment Period and not responsive at Week 24 (ie, not achieving ≥30% improvement from baseline in SALT [SALT 30]) who were continually assigned to PF-06651600 in the Non-Responder Segment of the SBE Period</description>
          </group>
          <group group_id="O2">
            <title>Active Non-responders on PF-06700841</title>
            <description>Participants initially treated with PF-06700841 in the Initial 24-Week Treatment Period and not responsive at Week 24 (ie, not achieving SALT 30) who were continually assigned to PF-06700841 in the Non-Responder Segment of the SBE Period</description>
          </group>
          <group group_id="O3">
            <title>Placebo Non-responders on PF-06651600</title>
            <description>Participants initially treated with placebo in the Initial 24-Week Treatment Period (1 participant receiving placebo in the Initial 24-Week Treatment Period was responsive at Week 24 but did not enter the SBE Period) who were assigned to PF-06651600 in the Non-Responder Segment of the SBE Period</description>
          </group>
          <group group_id="O4">
            <title>Placebo Non-responders on PF-06700841</title>
            <description>Participants initially treated with placebo in the Initial 24-Week Treatment Period who were assigned to PF-06700841 in the Non-Responder Segment of the SBE Period</description>
          </group>
          <group group_id="O5">
            <title>Retreated PF-06651600 Responders in the Retreatment Segment</title>
            <description>Participants initially treated with PF-06651600 in the Initial 24-Week Treatment Period and responsive at Week 24 (ie, achieving SALT 30) who were assigned to placebo (withdrawal), and then entered the Retreatment Segment of the SBE Period to receive PF-06651600</description>
          </group>
          <group group_id="O6">
            <title>Retreated Responders on PF-06700841 in the Retreatment Segment</title>
            <description>Participants initially treated with PF-06700841 in the Initial 24-Week Treatment Period and responsive at Week 24 (ie, achieving SALT 30) who were assigned to placebo (withdrawal), and then entered the Retreatment Segment of the SBE Period to receive PF-06700841</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving SALT 100 Across Time (SBE Period)</title>
          <description>SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 100 response is a 100% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method.</description>
          <population>All participants in the Full analysis set (FAS) was used. FAS consisted of all randomized participants, assigned to the randomized treatment regardless of what treatment, if any, was received.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 30/ AT Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-6.3" upper_limit="17.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-7.4" upper_limit="45.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-6.2" upper_limit="16.2"/>
                    <measurement group_id="O4" value="0.0" lower_limit="-6.3" upper_limit="22.1"/>
                    <measurement group_id="O5" value="0.0" lower_limit="-6.8" upper_limit="19.3"/>
                    <measurement group_id="O6" value="0.0" lower_limit="-6.6" upper_limit="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32/ AT Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-6.3" upper_limit="17.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-7.4" upper_limit="45.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-6.2" upper_limit="16.2"/>
                    <measurement group_id="O4" value="0.0" lower_limit="-6.3" upper_limit="22.1"/>
                    <measurement group_id="O5" value="0.0" lower_limit="-6.8" upper_limit="19.3"/>
                    <measurement group_id="O6" value="0.0" lower_limit="-6.6" upper_limit="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 34/ AT Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-6.3" upper_limit="17.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-7.4" upper_limit="45.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-6.2" upper_limit="16.2"/>
                    <measurement group_id="O4" value="0.0" lower_limit="-6.3" upper_limit="22.1"/>
                    <measurement group_id="O5" value="0.0" lower_limit="-6.8" upper_limit="19.3"/>
                    <measurement group_id="O6" value="0.0" lower_limit="-6.6" upper_limit="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36/ AT Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-6.3" upper_limit="17.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-7.4" upper_limit="45.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-6.2" upper_limit="16.2"/>
                    <measurement group_id="O4" value="0.0" lower_limit="-6.3" upper_limit="22.1"/>
                    <measurement group_id="O5" value="0.0" lower_limit="-6.8" upper_limit="19.3"/>
                    <measurement group_id="O6" value="0.0" lower_limit="-6.6" upper_limit="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40/ AT Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-6.3" upper_limit="17.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-7.4" upper_limit="45.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-6.2" upper_limit="16.2"/>
                    <measurement group_id="O4" value="8.3" lower_limit="-1.5" upper_limit="33.9"/>
                    <measurement group_id="O5" value="7.1" lower_limit="-1.9" upper_limit="29.7"/>
                    <measurement group_id="O6" value="0.0" lower_limit="-6.6" upper_limit="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44/ AT Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-6.3" upper_limit="17.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-7.4" upper_limit="45.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-6.2" upper_limit="16.2"/>
                    <measurement group_id="O4" value="8.3" lower_limit="-1.5" upper_limit="33.9"/>
                    <measurement group_id="O5" value="7.1" lower_limit="-1.9" upper_limit="29.7"/>
                    <measurement group_id="O6" value="13.3" lower_limit="2.1" upper_limit="36.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48/ AT Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-6.3" upper_limit="17.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-7.4" upper_limit="45.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-6.2" upper_limit="16.2"/>
                    <measurement group_id="O4" value="8.3" lower_limit="-1.5" upper_limit="33.9"/>
                    <measurement group_id="O5" value="7.1" lower_limit="-1.9" upper_limit="29.7"/>
                    <measurement group_id="O6" value="20.0" lower_limit="5.7" upper_limit="44.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52/ AT Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-6.3" upper_limit="17.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-7.4" upper_limit="45.1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-6.2" upper_limit="16.2"/>
                    <measurement group_id="O4" value="8.3" lower_limit="-1.5" upper_limit="33.9"/>
                    <measurement group_id="O5" value="14.3" lower_limit="2.4" upper_limit="38.5"/>
                    <measurement group_id="O6" value="20.0" lower_limit="5.7" upper_limit="44.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose of study treatment up to 113 weeks</time_frame>
      <desc>The same event may appear as both an AE and an SAE. However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as non-serious in another participant, or 1 participant may have experienced both a serious and non-serious event during the study.&#xD;
Participants were counted only once per treatment per event.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment Period-Placebo</title>
          <description>Participants received placebo tablets QD both matching for PF-06651600 and PF-06700841</description>
        </group>
        <group group_id="E2">
          <title>Treatment Period-PF-06651600</title>
          <description>Participants received PF-06651600 200 mg tablets QD for a 4-week induction period followed by PF-06651600 50 mg tablets QD for a 20-week maintenance period.</description>
        </group>
        <group group_id="E3">
          <title>Treatment Period-PF-06700841</title>
          <description>Participants received PF-06700841 60 mg tablets QD for a 4-week induction period followed by PF-06700841 30 mg tablets QD for a 20-week maintenance period.</description>
        </group>
        <group group_id="E4">
          <title>Single Blind Extension-Active Non-responders on PF-06651600</title>
          <description>Participants initially treated with PF-06651600 in the Initial 24-Week Treatment Period and not responsive at Week 24 (ie, not achieving ≥30% improvement from baseline in SALT [SALT 30]) who were continually assigned to PF-06651600 in the Non-Responder Segment of the SBE Period</description>
        </group>
        <group group_id="E5">
          <title>Single Blind Extension-Placebo Non-responders on PF-06651600</title>
          <description>Participants initially treated with placebo in the Initial 24-Week Treatment Period (1 participant receiving placebo in the Initial 24-Week Treatment Period was responsive at Week 24 but did not enter the SBE Period) who were assigned to PF-06651600 in the Non-Responder Segment of the SBE Period</description>
        </group>
        <group group_id="E6">
          <title>Single Blind Extension-Active Non-responders on PF-06700841</title>
          <description>Participants initially treated with PF-06700841 in the Initial 24-Week Treatment Period and not responsive at Week 24 (ie, not achieving SALT 30) who were continually assigned to PF-06700841 in the Non-Responder Segment of the SBE Period</description>
        </group>
        <group group_id="E7">
          <title>Single Blind Extension-Placebo Non-responders on PF-06700841</title>
          <description>Participants initially treated with placebo in the Initial 24-Week Treatment Period who were assigned to PF-06700841 in the Non-Responder Segment of the SBE Period</description>
        </group>
        <group group_id="E8">
          <title>SBE-Non-Retreated PF-06651600 Responders in Withdrawal Segment</title>
          <description>Participants initially treated with PF-06651600 in the Initial 24-Week Treatment Period and responsive at Week 24 (ie, achieving SALT 30) who were assigned to placebo (withdrawal) without entering the Retreatment Segment of the SBE Period</description>
        </group>
        <group group_id="E9">
          <title>SBE-Retreated PF-06651600 Responders in Withdrawal Segment</title>
          <description>Participants initially treated with PF-06651600 in the Initial 24- Week Treatment Period and responsive at Week 24 (ie, achieving SALT 30) who were assigned to placebo (withdrawal), and then entered the Retreatment Segment of the SBE Period to receive PF-06651600.&#xD;
This arm described AEs for retreated responders within withdrawal Segment.</description>
        </group>
        <group group_id="E10">
          <title>SBE-Non-Retreated PF-06700841 Responders (Withdrawal Segment)</title>
          <description>Participants initially treated with PF-06700841 in the Initial 24-Week Treatment Period and responsive at Week 24 (ie, achieving SALT 30) who were assigned to placebo (withdrawal) without entering the Retreatment Segment of the SBE Period</description>
        </group>
        <group group_id="E11">
          <title>SBE-Retreated PF-06700841 Responders in the Withdrawal Segment</title>
          <description>Participants initially treated with PF06700841 in the Initial 24- Week Treatment Period and responsive at Week 24 (ie, achieving SALT 30) who were assigned to placebo (withdrawal), and then entered the Retreatment Segment of the SBE Period to receive PF-06700841.This arm described AEs for retreated responders within Withdrawal Segment</description>
        </group>
        <group group_id="E12">
          <title>SBE-Retreated PF-06651600 Responders in Retreatment Segment</title>
          <description>Participants initially treated with PF-06651600 in the Initial 24-Week Treatment Period and responsive at Week 24 (ie, achieving SALT 30) who were assigned to placebo (withdrawal), and then entered the Retreatment Segment of the SBE Period to receive PF-06651600</description>
        </group>
        <group group_id="E13">
          <title>SBE-Retreated Responders on PF-06700841 in Retreatment Segment</title>
          <description>Participants initially treated with PF-06700841 in the Initial 24-Week Treatment Period and responsive at Week 24 (ie, achieving SALT 30) who were assigned to placebo (withdrawal), and then entered the Retreatment Segment of the SBE Period to receive PF-06700841</description>
        </group>
        <group group_id="E14">
          <title>Cross Over Extension-PF-06651600</title>
          <description>Participants not responsive to placebo or PF-06700841 at Week 24 in the Initial 24-Week Treatment Period and not responsive to PF-06700841 at Week 52 (ie, not achieving SALT 30) in the SBE Period who were assigned to PF-06651600 in the COE Period</description>
        </group>
        <group group_id="E15">
          <title>Cross Over Extension-PF-06700841</title>
          <description>Participants not responsive to placebo or PF-06651600 at Week 24 in the Initial 24-Week Treatment Period and not responsive to PF-06651600 at Week 52 (ie, not achieving SALT 30; except 1 PF-06651600 responder) in the SBE Period who were assigned to PF-06700841 in the COE Period</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v22.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA v22.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="9" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="11" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="8" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="8" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eyelids pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Lip oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Sinusitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Tinea versicolour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Arthritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Bartholin's abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Glomerular filtration rate decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Torticollis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Taste disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>IgA nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Keratosis pilaris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Madarosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Papulopustular rosacea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Pseudofolliculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Urticaria papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hidradenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02974868
org study id: B7931005
secondary id: 2016-004048-13
secondary id: ALLEGRO
nct id: NCT02974868
lead sponsor: 
has dmc: Yes
is fda regulated drug: Yes
is fda regulated device: No
This is a Phase 2a, randomized, double blind, parallel group, multicenter study with an
      extension period. The study will have a maximum duration of approximately 113 weeks. This
      includes an up to 5 weeks Screening Period, a 24 week Treatment Period, a 4 week Drug Holiday
      (#1), an up to 12 month Single Blind (investigator open, sponsor open and subject blind)
      Extension Period, a 4 week drug holiday (#2), a 6 month Cross Over Open Label Extension
      Period and a 4 week Follow up Period.
allocation: Randomized
intervention model description: The first 24 weeks are parallel. The single-blind extension period will have a segment for non-responder and a withdrawal/retreatment segment for responder. The cross-over extension period is parallel for non-responders.
primary purpose: Treatment
masking: Triple (Participant, Investigator, Outcomes Assessor)
measure: Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24
time frame: Baseline, Week24
description: SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. Score range: 0-100%. Higher score indicates more severe disease. Change from baseline is defined as the baseline value minus the value at a specific visit. Positive change from baseline signifies an improvement. Baseline is defined as the last measurement prior to first dosing (Day 1).
measure: Number of Participants With Treatment-emergent Adverse Events (All-causality and Treatment-related) - Single-Blind Extension (SBE) Period
time frame: Week 28 up to Week 52
description: An AE (non-serious and serious) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent Adverse Event (TEAE). Treatment-related TEAE were determined by investigators. Arms end with "withdrawal Segment" and "retreatment segment" described the same population while in different treatment segment .The reason why count on PF-06700841 differ by 1 participant is that 1 responder directly entered the retreatment segment and skipped the withdrawal segment.
measure: Number of Participants With Treatment-emergent Adverse Events (All-causality and Treatment-related) - Cross-Over Extension (COE) Period
time frame: COE day 1 up to end of study
description: An AE (non-serious and serious) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent Adverse Event (TEAE). Treatment-related TEAE were determined by investigators.
measure: Number of Participants With Laboratory Abnormalities During SBE Period
time frame: Week 28 up to Week 52 for non-responders and responders in the withdrawal segment, AT day 1 up to AT Week 24 for retreatment segment (AT=active treatment)
description: Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology(Hemoglobin, Hematocrit, RBC count, Reticulocyte count, Platelet count, WBC count with differential, Total neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes); serum chemistry (BUN and Creatinine, Cystatin C, Creatine Phosphokinase, Glucose , Na+, K+, Cl ,Ca++, Total CO2, AST, ALT, Total Indirect & Direct Bilirubin, Alkaline phosphatase, Uric acid, Albumin,Total protein, Fasting lipid Profile Panel; urinalysis(pH, Glucose, Protein, Nitrites, Leukocyte esterase, Microscopy culture);Other(HIV, HBsAg, HBcAb, HepB reflex (HbsAB), if applicable, HCVAb, Serum pregnancy test, Urine pregnancy test, FSH, QFT G or other IGRA, or PPD, EBV, CMV, HSV1, HSV2, VZV, Skin swab for herpetiform rash, Skin swab for potential drug related rash).Retest/discontinuation criteria are defined in Protocol Appendix 6.1 and 6.2 respectively.
measure: Numbers of Participants With Specific Clinical Laboratory Abnormalities During COE Period
time frame: COE day 1 up to end of study
description: Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology(Hemoglobin, Hematocrit, RBC count, Reticulocyte count, Platelet count, WBC count with differential, Total neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes); serum chemistry (BUN and Creatinine, Cystatin C, Creatine Phosphokinase, Glucose , Na+, K+, Cl ,Ca++, Total CO2, AST, ALT, Total Indirect & Direct Bilirubin, Alkaline phosphatase, Uric acid, Albumin,Total protein, Fasting lipid Profile Panel; urinalysis(pH, Glucose, Protein, Nitrites, Leukocyte esterase, Microscopy culture);Other(HIV, HBsAg, HBcAb, HepB reflex (HbsAB), if applicable, HCVAb, Serum pregnancy test, Urine pregnancy test, FSH, QFT G or other IGRA, or PPD, EBV, CMV, HSV1, HSV2, VZV, Skin swab for herpetiform rash, Skin swab for potential drug related rash).Retest/discontinuation criteria are defined in Protocol Appendix 6.1 and 6.2 respectively.
measure: Change From Baseline in Severity of Alopecia Tool (SALT) Score at Week 24 -AT/AU Participants
time frame: Baseline, Week 24
description: SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. Change from baseline is defined as the baseline value minus the value at a specific visit. Positive change from baseline implies an improvement. Alopecia totalis (AT): derived as SALT score = 100% at baseline only. Alopecia universalis (AU): derived as SALT score = 100% and both eyelash and eyebrow assessments were "none" at baseline.
measure: Percentage of Participants Achieving SALT 30 at Week 24
time frame: Baseline, Week 24
description: SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 30 response is a 30% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The 90% CI was calculated using Chan and Zhang method.
measure: Change From Baseline in Severity of Alopecia Tool (SALT) Across Time (Treatment Period)
time frame: Baseline, Weeks 2,4,6,8,12,16,20,24
description: SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. The SALT score can vary from 0 to 100% with higher score indicates more severe disease. Baseline is defined as the last measurement prior to first dosing (Day 1). Change from baseline is defined as the baseline value minus the value at a specific visit. Positive change from baseline implies an improvement. Least Square Mean and 90% Confidence Interval of Arms (PF-06651600 and PF-06700841) are the Least Square Mean and 90% Confidence Interval for difference from placebo respectively.
measure: Percent Change From Baseline in Severity of Alopecia Tool (SALT) Across Time (Treatment Period)
time frame: Baseline, Weeks 2,4,6,8,12,16,20,24
description: SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. The SALT score can vary from 0 to 100% with higher score indicates more severe disease. Baseline is defined as the last measurement prior to first dosing (Day 1). Percent change from baseline is defined as SALT baseline value minus SALT value at a specific visit divided by baseline and multiplying by 100. Positive change from baseline implies an improvement. Least Square Mean and 90% Confidence Interval of Arms (PF-06651600 and PF-06700841) are the Least Square Mean and 90% Confidence Interval for difference from placebo respectively.
measure: Percentage of Participants Achieving SALT 30 Across Time (Treatment Period)
time frame: Baseline, Weeks 2,4,6,8,12,16,20,24
description: SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 30 response is a 30% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method.
measure: Percentage of Participants Achieving SALT 50 Across Time (Treatment Period)
time frame: Baseline, Weeks 2,4,6,8,12,16,20,24
description: SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 50 response is a 50% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method.
measure: Percentage of Participants Achieving SALT 75 Across Time (Treatment Period)
time frame: Baseline, Weeks 2,4,6,8,12,16,20,24
description: SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 75 response is a 75% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method.
measure: Percentage of Participants Achieving SALT 90 Across Time (Treatment Period)
time frame: Baseline, Weeks 2,4,6,8,12,16,20,24
description: SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 90 response is a 90% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method.
measure: Percentage of Participants Achieving SALT 100 Across Time (Treatment Period)
time frame: Baseline, Weeks 2,4,6,8,12,16,20,24
description: SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 100 response is a 100% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) of Arms(PF-06651600 and PF-06700841) in this outcome measurement is the percentage and 90% CI for difference from placebo. The 90% CI was calculated using Chan and Zhang method.
measure: Number of Participants With the IGA Score Change (Treatment Period)
time frame: baseline, Week 2,4,6,8,12,16,20,24
description: The clinical evaluator of alopecia areata (AA) will perform an assessment of the overall improvement of AA and assign an Investigator Global Assessment (IGA) score(ranging from 0 to 5) with higher score representing higher regrowth rate. Baseline is defined as the last measurement prior to first dosing (Day 1).
measure: Number of Participants With Treatment-emergent Adverse Events (All-causality and Treatment-related) - Treatment Period
time frame: baseline up to Week 24
description: An AE (non-serious and serious) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent Adverse Event (TEAE). Treatment-related TEAE were determined by investigators.
measure: Number of Participants With Laboratory Abnormalities During Treatment Period
time frame: Baseline up to Week 24
description: Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology(Hemoglobin, Hematocrit, RBC count, Reticulocyte count, Platelet count, WBC count with differential, Total neutrophils, Eosinophils, Monocytes, Basophils, Lymphocytes); serum chemistry (BUN and Creatinine, Cystatin C, Creatine Phosphokinase, Glucose , Na+, K+, Cl ,Ca++, Total CO2, AST, ALT, Total Indirect & Direct Bilirubin, Alkaline phosphatase, Uric acid, Albumin,Total protein, Fasting lipid Profile Panel; urinalysis(pH, Glucose, Protein, Nitrites, Leukocyte esterase, Microscopy culture);Other(HIV, HBsAg, HBcAb, HepB reflex (HbsAB), if applicable, HCVAb, Serum pregnancy test, Urine pregnancy test, FSH, QFT G or other IGRA, or PPD, EBV, CMV, HSV1, HSV2, VZV, Skin swab for herpetiform rash, Skin swab for potential drug related rash).Retest/discontinuation criteria are defined in Protocol Appendix 6.1 and 6.2 respectively.
measure: Time to Achieve the Retreatment Criteria During the Withdrawal/Retreatment Part of the Extension Period Among Subjects Who Achieved Primary Endpoint at Week 24 (SBE Period)
time frame: Week 24 up to Week 52
description: Time to re-treatment (weeks) = (date of re-treatment criteria met - date at Week 24 +1)/7. The calendar time to retreatment was calculated. Baseline is defined as Week 24 measurement. The duration in Drug Holiday #1 (ranging from 2-6 weeks) is counted in the Kaplan-Meier analysis. One subject directly entered the re-treatment period and hence is censored at baseline in the Kaplan-Meier analysis.
measure: Change From Baseline in SALT Across Time (SBE Period)
time frame: Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)
description: SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. The SALT score can vary from 0 to 100% with higher score indicates more severe disease. Baseline is defined as the last measurement prior to first dosing (Day 1). Change from baseline is defined as the baseline value minus the value at a specific visit. Positive change from baseline implies an improvement. Least Square Mean and 90% confidence interval in this outcome measurement is the LSM and 90%CI for difference from initial 24-week treatment period placebo respectively.
measure: Percentage of Participants Achieving SALT 30 Across Time (SBE Period)
time frame: Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)
description: SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 30 response is a 30% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method.
measure: Percentage of Participants Achieving SALT 50 Across Time (SBE Period)
time frame: Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)
description: SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 50 response is a 50% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method.
measure: Percentage of Participants Achieving SALT 75 Across Time (SBE Period)
time frame: Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)
description: SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 75 response is a 75% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method.
measure: Percentage of Participants Achieving SALT 90 Across Time (SBE Period)
time frame: Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)
description: SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 90 response is a 90% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method.
measure: Percentage of Participants Achieving SALT 100 Across Time (SBE Period)
time frame: Weeks 30, 32, 34, 36, 40, 44, 48, 52 for non-responders, and AT Weeks 2, 4, 6, 8, 12, 16, 20, 24 for retreated responders.(AT=active treatment)
description: SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 100 response is a 100% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease. The analysis was done using FAS (full analysis set) based on Non-responder imputation (ie. set missing values to be non-responsive) data. The percentage(Number) and 90% confidence interval (CI) in this outcome measurement is the percentage and 90% CI for difference from initial 24-week treatment period placebo. The 90% CI was calculated using Chan and Zhang method.
arm group label: Cohort 1
arm group type: Experimental
description: PF-06651600
arm group label: Cohort 2
arm group type: Experimental
description: PF-06700841
arm group label: Cohort placebo
arm group type: Placebo Comparator
description: placebo
intervention type: Drug
intervention name: PF-06651600
description: 200 mg QD during induction and 50 mg QD during Maintenance
arm group label: Cohort 1
intervention type: Drug
intervention name: PF-06700841
description: 60 mg QD during induction and 30 mg QD during maintenance
arm group label: Cohort 2
intervention type: Drug
intervention name: Placebo
description: Placebo
arm group label: Cohort placebo
criteria: 
gender: All
minimum age: 18 Years
maximum age: 75 Years
healthy volunteers: No
last name: Pfizer CT.gov Call Center
role: Study Director
affiliation: Pfizer
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: Australia
country: Canada
country: United States
url: https://pmiform.com/clinical-trial-info-request?StudyID=B7931005
description: To obtain contact information for a study center near you, click here.
responsible party type: Sponsor
mesh term: Alopecia
mesh term: Alopecia Areata
mesh term: PF-06700841
sharing ipd: Yes
ipd description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
ipd url: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests
provided document: 
provided document: 
participant flow: 
baseline: 
outcome list: 
reported events: 
certain agreements: 
point of contact: 